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Preface
The Australian Institute of Health and Welfare (AIHW) and the Australasian Association of
Cancer Registries (AACR) are pleased to present Cancer in Australia 1999, the most recent
report generated from the National Cancer Statistics Clearing House.
This report contains updates of the national cancer incidence and mortality data found in
previous editions, and presents summary cancer statistics for several other national data
sources held by the Australian Institute of Health and Welfare. These include screening,
survival and multiple cause of death statistics; general practice patient encounter and
hospital inpatient data showing broad patient treatment patterns for the first time; cancer
workforce numbers; and trends in some of the major known risk factors. These statistics are
supplemented by additional tables, a national cancer data cube and further reports on the
AIHW web site at www.aihw.gov.au. There is a wealth of State and Territory cancer data
and many cancer research reports found on the State and Territory cancer registry web sites
listed in Appendix E. ‘Related publications’ lists many of the published reports available
from State and Territory registries.
The AACR and the AIHW wish to acknowledge the efforts of all the cancer registries in
compiling and providing data to the National Cancer Statistics Clearing House so that this
report could be published. A considerable amount of work was undertaken by AIHW and
AACR in implementing the changeover in reporting of cancer incidence data in this
publication from International Classification of Diseases (ICD) version 9 to ICD version 10.
While this caused some delay in the publication of this report, AIHW and AACR are hopeful
that the transition work undertaken this time will assist in improving timeliness and the
quality of the information for the next report.
Richard Madden
Director
Australian Institute of Health and Welfare
Professor Graham Giles
Chair
Australasian Association of Cancer Registries
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Executive summary
This report presents national cancer incidence and mortality statistics for 1999 and
cancer-related risk factor, screening, survival and treatment data and associated workforce
data. It is part of a series of publications concerning cancer patterns in Australia. The State
and Territory cancer registries provide the incidence data for this report whereas the
mortality data are provided by the State and Territory Registrars of Births, Deaths and
Marriages and coded by the Australian Bureau of Statistics. Other data sources include:
• AIHW National Hospital Morbidity Database;
• AIHW General Practice Statistics and Classification Unit; and
• AIHW health workforce collections.
The main findings are as follows.
New cases of cancer and mortality
• Excluding non-melanocytic skin cancers, there were 82,185 new cancer cases and 34,695
deaths due to cancer in Australia in 1999. At the incidence rates prevailing in 1999, it
would be expected that 1 in 3 men and 1 in 4 women would be directly affected by cancer
in the first 75 years of life. Further, an estimated 254,000 potential years of life would be
lost to the community as a result of people dying of cancer in 1999 before the age of 75.
Cancer currently accounts for 29% of male deaths and 25% of female deaths.
Cancers in males and females
• In males, prostate cancer (10,232 new cases diagnosed in 1999) is the most common
registrable cancer, followed by colorectal cancer (6,188), lung cancer (5,275) and
melanoma (4,627). These four cancers account for 59% of all registrable cancers in males.
• In females, breast cancer (10,592) is the most common registrable cancer, followed by
colorectal cancer (5,449), melanoma (3,616) and lung cancer (2,551). These four cancers
account for 59% of all registrable cancers in females.
Most common cancers causing death
• The most common cancers causing death are lung (4,645 deaths in 1999), prostate (2,512)
and colorectal (2,483) cancers in males, and breast (2,512), lung (2,123) and colorectal
(2,092) cancers in females.
Age distribution
• The risk of cancer increases with age, with over four times as many cancers diagnosed in
those over the age of 60 as in those under 60.
Trends
• In 1990 there were 62,435 new cases of cancer diagnosed (excluding non-melanocytic skin
cancers)—33,915 for males (a rate of 452.1 per 100,000 population) and 28,520 for females
(a rate of 315.0 per 100,000 population). This rose to 82,185 new cases in 1999—44,514 for
males (a rate of 469.6 per 100,000 population) and 37,671 for females (a rate of 339.2 per
100,000 population).
• Between 1990 and 1999, age-standardised incidence rates for all cancers combined
(except non-melanocytic skin cancers) rose for both males and females by an average of
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0.3% and 0.8% per year, respectively, but death rates declined for both males and females
by an average of 1.1% and 1.0% per year, respectively.
• A significant proportion of the rise in female incidence rates can be attributed to the
continuing increase of breast cancer incidence which in turn can be attributed in part to
detection of prevalent cancers by the breast screening programs. The recent fall in male
incidence rates is strongly influenced by the decline in prostate and lung cancer rates.
The introduction of prostate-specific antigen testing and its later fall in use has induced
the rapid rise and subsequent fall in the rates of the incidence of prostate cancer in recent
years.
• Cervical cancer incidence and mortality between 1990 and 1999 fell rapidly by an average
of 5.4% and 5.5% per annum, respectively.
Cancer mortality—multiple causes of death
• In Australia in 1999 there were 35,053 deaths where the underlying cause was malignant
cancer and 11,714 additional deaths where cancer was an associated cause reported on
the death certificate.
Survival following cancer diagnosis
• The average 5-year relative survival proportion for all registrable cancers diagnosed in
Australia in the period 1992–1997 was 56.8% for males and 63.4% for females.
• For registrable cancers diagnosed in males during the period 1992–1997, relative survival
in capital cities, other metropolitan areas and large rural centres was close to 57.5%. This
was significantly above the proportions in small rural centres (55.2%) and ‘other remote’
areas (51.9%). There were no statistically significant differences in relative survival for
females between metropolitan, rural and remote areas.
• For males diagnosed during the period 1992–1997, relative survival was 51.9% for
persons resident in the most disadvantaged areas of Australia, and 61.4% for residents of
the most advantaged areas. For females, there was a lesser disparity, with a relative
survival of 61.9% in the bottom quintile and 63.4% in the highest. This may be partly
attributed to higher rates of breast cancer in women living in higher socioeconomic status
areas.
• 5-year relative survival for all registrable cancers increased between 1982–1986 and 1992–
1997 on average from 43.8% to 56.8% for males and from 55.3% to 63.4% for females.
Risk factors
• In Australia, smoking rates have been declining since the 1950s, when it was estimated
that around 70% of males and 30% of females smoked.
• Cigarette smoking is estimated to have directly caused 10,619 new cases of cancer (12.9%
of all new cases of cancer) and 7,554 deaths (21.8% of cancer deaths) in 1999. Between
1990 and 1999, the male incidence rate for smoking-related cancers fell by an average of
1.4% per year, while the rate for females rose by 0.8% per year. Over the same period,
mortality rates fell by 1.7% for males and rose by 0.8% for females per annum.
• Hospital separations for each of the eight National Health Priority Area cancers included
hypertension, current tobacco use and personal history of tobacco use in their top ten
additional diagnoses.
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• Alcohol consumption is known to be a contributing cause of cancers of the liver,
laryngeal, oropharyngeal, oesophagus, and the female breast. Australia’s drinking
pattern has remained largely unchanged over the last decade.
• It is estimated that 2,602 new cases of cancer were directly attributable to alcohol
consumption in 1999 at a rate of 13.7 cases per 100,000 population, as were 1,199 deaths
at a rate of 6.3 per 100,000 population.
Screening
• The proportion of women in the target age group (ages 50 to 69) who were screened
under the BreastScreen Australia program in a 2-year period rose from 51.4% in the
period 1996–1997 to 55.9% in the period 1998–1999.
• The proportion of women in the target age group who were screened under the National
Cervical Cancer Screening Program in a 2-year period rose from 62.3% in the period
1996–1997 to 64.8% in the period 1998–1999.
Hospital inpatients with cancer
• In the financial year 2000–01 there were 306,536 hospital separations where cancer was
recorded as the principal diagnosis. This represents 5.0% of all separations in that year.
• Non-melanocytic skin cancer was the principal diagnosis associated with the greatest
number of separations. This cancer had the largest proportion of same-day patients.
Colorectal cancer was the principal diagnosis associated with the longest average length
of stay for non-same-day patients.
Cancer workforce
• In 1998, there were 658 medical specialists working in the fields of medical and radiation
oncology, clinical haematology, haematology and nuclear medicine. These are fields of
practice with a high proportion of cancer patients. In addition, nearly all other doctors in
clinical practice in Australia provide services to at least some cancer patients.
• In 1997 there were 2,412 registered nurses and 273 enrolled nurses working in oncology
as their main field of nursing practice.
• In its 2001 report, the Australian Medical Workforce Advisory Committee (AMWAC)
reported that there were 337 medical and haematological oncologists in 2000, and there
was both a shortage of these oncologists and a maldistribution of the existing workforce.
AMWAC also reported that there were 1,148 specialist radiologists in 2000, and that this
workforce was also under supplied, together with the specialist radiation oncology
workforce.
General practice and cancer patients
• During the period April 1998 to March 2002, general practitioners managed cases of
cancer at a rate of 18.8 per 1,000 GP–patient encounters. Extrapolated to the total
GP–patient encounters in any one year across the country, these data suggest there are
about two million encounters in general practice in which a cancer is managed.
• The top ten types of cancer managed by GPs together accounted for around 78% of the
GP–patient contacts with a cancer. The top three types—basal and squamous cell
carcinoma and prostate cancer—accounted for around 51% of cancers managed. All skin
cancers (both melanoma and non-melanocytic skin cancers) together accounted for
around 46% of cancers managed at these encounters.
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11 Introduction
Cancer is a notifiable disease in all States and Territories and is the only major disease
category for which an almost complete coverage of incidence data is available. Cancer is also
a major cause of death in Australia. If this situation is to be changed, good information on
the occurrence of different types of cancer, the characteristics of patients, and survival and
mortality is essential. Such information facilitates the monitoring of trends and the impact of
interventions, and provides a sound basis for epidemiological studies and the initiation of
prevention and treatment programs.
What is cancer?
Cancer describes a range of diseases in which abnormal cells proliferate and spread out of
control. Other terms for cancer are tumours and neoplasms, although these terms can also be
used for non-cancerous growths.
Normally, cells grow and multiply in an orderly way to form organs that have a specific
function in the body. Occasionally, however, cells multiply in an uncontrolled way after
being affected by a carcinogen, or after developing from a random genetic mutation, and
form a mass which is called a tumour or neoplasm. Tumours can be benign (not a cancer) or
malignant (a cancer). Benign tumours do not invade other tissues or spread to other parts of
the body, although they can expand to interfere with healthy structures.
The main features of a malignant tumour (cancer) are its ability to grow in an uncontrolled
way and to invade and spread to other parts of the body (metastasise). Invasion occurs when
cancer cells push between and break through other surrounding cells and structures. Spread
to other parts of the body occurs when some cancer cells are carried by the bloodstream or
the lymphatic system and lodge some distance away. They can then start a new tumour (a
secondary cancer) and begin invading again. They can cause serious damage by destruction,
crushing or blocking.
Cancer can develop from most types of cells in different parts of the body, and each cancer
has its own pattern of growth and spread. Some cancers remain in the body for years
without showing any symptoms. Others can grow, invade and spread rapidly, and are fatal
in a short period of time. Apart from the cancer’s natural behaviour, its effects can also
depend on how much room it has before it damages nearby structures, and whether it starts
in a vital organ or is close to other vital organs.
Although a number of cancers share risk factors, most cancers have a unique set of risk
factors that are responsible for their onset. Some cancers occur as a direct result of smoking,
dietary influences, infectious agents or exposure to radiation (for example, ultraviolet
radiation), while others may be a result of inherited genetic faults. It should be noted that for
many cancers the causes are unknown. While some of the causes are modifiable through
lifestyle changes, some others are inherited and cannot be avoided. However, the risk of
death due to particular cancers may be reduced through intensive monitoring of individuals
at high risk, reducing external risk factors, detecting and treating cancers early in their
development, and treating them in accordance with the best available evidence.
2Many cancers can be serious and even fatal. However, medical treatment is often successful
if the cancer is detected early. The aim is to destroy the cancer cells and stop them from
returning. This can be done by surgery to remove the growth or by other methods such as
cancer-destroying drugs (chemotherapy) or ray treatment (radiation therapy). The growth of
some cancers can also be controlled through hormone therapy.
The treatment approach often combines a number of these methods and uses them in stages.
The first line of treatment aims to remove as many cancer cells as possible; the second line,
which may go on for a long time, aims to ensure the cancer does not recur.
Cancer surveillance in Australia
National data on cancer deaths have been available since the early 1900s, based on
information in medical certificates of cause of death, as provided to the Registrar of Births,
Deaths and Marriages in each State and Territory. The Australian Institute of Health and
Welfare (AIHW) and the Australian Bureau of Statistics (ABS) use these data to report
national cause of death statistics. Information concerning cancer deaths and non-cancer
deaths of cancer cases is also collected by State and Territory cancer registries, based on
death certificates and other diagnostic information.
The only effective method of obtaining cancer incidence data is through universal
registration of cancer diagnoses. In Australia, cancer registration is required under State and
Territory legislation. The cancer registrations are collated by cancer registries that are
supported by a mix of State and Territory government and non-government organisations.
Some State and Territory cancer registries have been operating for nearly 30 years and
obtain their information from hospital, pathology, radiotherapy and physician records
(Appendix D). It was not until 1982, however, that cancer registration was universal in
Australia (data were published in Cancer in Australia 1982 (Giles, Armstrong & Smith 1987).
Before then, there was no registration in some States and in some others registries covered
only particular areas, hospitals or cancer sites.
The National Cancer Statistics Clearing House
In June 1984 the National Health and Medical Research Council endorsed the concept of a
national collection of cancer statistics. In April 1985 the National Committee on Health and
Vital Statistics agreed that the National Cancer Statistics Clearing House (NCSCH) should be
operated by the then Australian Institute of Health under the supervision of the Australasian
Association of Cancer Registries (AACR).
Following the enactment of Commonwealth legislation establishing the then Australian
Institute of Health as a statutory body in 1987, and subsequent legislation providing for the
protection of confidentiality of records supplied to it, the Institute and the AACR established
the NCSCH. This provides a facility for compiling data produced by individual State and
Territory registries on a continuing basis.
The aim of the NCSCH is to foster the development and dissemination of national cancer
statistics for Australia and specifically to:
• enable computation and publication of national statistics on cancer;
• allow tracking of interstate movement of cancer cases via record linkage;
3• facilitate exchange of scientific and technical information between cancer registries and
promote standardisation in the collection and classification of cancer data; and
• facilitate cancer research both nationally and internationally.
The NCSCH receives data from individual State and Territory cancer registries on cancers
diagnosed in residents of Australia. This commenced with cases first diagnosed in 1982. The
data items provided to the NCSCH by the State and Territory cancer registries enable record
linkage to be performed and the analysis of cancer by site and behaviour.
The NCSCH produces reports of national incidence and mortality data. Periodically,
analyses of specific cancer sites, cancer histology, differentials in cancer rates by country of
birth, geographical variation, trends over time and survival are undertaken on an
accumulation of data which permits examination of the data in greater depth. The section
‘Related publications’ sets out the range of publications based on these data.
The NCSCH is able to make available a broad range of statistical data. Data identifying
individuals may only be released to bona fide researchers after a strict scientific and ethical
review process which involves the AACR executive, the AIHW Health Ethics Committee
and the State and Territory cancer registries. General database enquiries and enquiries about
the release of statistical data should be addressed to:
Australian Institute of Health and Welfare
National Cancer Statistics Clearing House
Attention: Dr Chris Stevenson
GPO Box 570
Canberra ACT 2601
Phone: (02) 6244 1041
E-mail: chris.stevenson@aihw.gov.au
Other sources of data on cancer
In addition to the NCSCH, the AIHW holds several other national databases containing
cancer-related data. Many factors determine and influence health. Indeed, the dominant
view presently is a ‘multicausal’ one, in which disease, disability and (ultimately) death are
to be seen as the result of the interaction of human biology, lifestyle and environmental
(including social) factors, modified by healthcare interventions. Therefore, while the main
focus of this report is the presentation of cancer incidence and mortality data, it also includes
summary data from these other databases which contribute to a more complete picture of
cancer in Australia.
Figure 1 presents a conceptual framework for health (AIHW 2002a). Disability, disease and
death are aspects of health and wellbeing, and can be seen as the result of a complex
interplay of many factors described as individual or environmental. These causes and effects
can be modified to various degrees by health protection, prevention and promotion, or by
treatment and rehabilitation; in the end stages of life, palliation services feature. Such
interventions are supported by human and material resources, including essential
information via research, monitoring and evaluation.
The incidence and mortality data presented in this report contribute to the parts of the
framework under ‘Health, functioning and wellbeing’. The data in Chapter 5 (multiple
causes of death, survival, screening and treatment) extend the coverage of this part of the
framework. Chapter 5 also contributes to the ‘Resources’ part of the framework with a
4discussion of the health workforce implications for cancer and to the ‘Determinants of
health’ part of the framework with a discussion of cancer-related risk factors.
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      Figure 1: A conceptual framework for health
There are still significant gaps in cancer-related national data collections. For example, there
are still no national data collections of hospital outpatient services and only limited data in
areas such as palliative care.
5Structure of this report
This report is divided into six major components:
• an introduction and overview of cancer in Australia in 1999;
• summary tables of incidence and mortality for all cancer sites for 1999;
• a series of incidence and mortality data tables for the most common cancer sites, and
some less common but topical cancer sites, for 1999;
• an overview of some additional sources of data on cancer in Australia covering cancer
survival, risk factors, screening, treatment and workforce issues;
• glossary and reference sections;
• appendixes comprising the cancer coding system and methods used in this report and
State and Territory registration features.
In addition, a full set of statistical tables are published separately on the AIHW’s web site at
www.aihw.gov.au. Also on the web site are two interactive data cubes with cancer incidence
data for Australia for 1983–1999. An interactive data cube is a multidimensional
representation of data. It contains information organised into dimensions to provide fast
retrieval of data and cross-tabulation facilities.
Introduction and overview
The overview of cancer in Australia provides a selection of highlights from the data tables. It
describes the patterns of cancer incidence and mortality by site, age, sex, and State and
Territory. Trends in cancer incidence and mortality are discussed and a series of graphs are
provided presenting the most common cancers by sex and age group, and trends in national
cancer incidence (1983–1999) and mortality (1983–2000).
Summary tables
Summary tables of incidence and mortality for 1998 for all cancer sites are provided. These
tables list numbers of new cases and deaths, and crude and age-standardised incidence and
mortality rates for Australia. Cumulative rates are given for incidence, while the mortality
tables provide estimates of the person-years of life lost. Sex ratios are presented in both the
incidence and mortality tables.
Series of data tables
The series of data tables for the most common or topical cancers in 1999 contain age-specific,
crude, and age-standardised incidence and mortality rates for males, females and persons for
each cancer site. The order of the tables is based on the International Classification of
Diseases 10th Revision (World Health Organization 1992) (Appendix A). All rates are
expressed per 100,000 population and, at the Australian level, are directly age standardised
(Appendix B) to both the total estimated resident population of Australia at 30 June 1991 and
the new WHO World Standard Population (Appendix C). Included in these tables are
estimates of the lifetime risk of contracting each cancer, the person-years of life lost and the
numbers of each cancer as a proportion of the total (excluding non-melanocytic skin cancers).
6The data tables also include average annual numbers of new cancer cases and deaths, and
age-standardised incidence and mortality rates for each State and Territory. It should be
noted that the State and Territory incidence and mortality rates have been directly age
standardised to the total estimated resident population of Australia at 30 June 1991.
Particular care should be taken not to compare these State and Territory rates with previous
Cancer Series publications—Cancer in Australia 1989–1990 (with Projections to 1995), Cancer in
Australia 1986–1988 or Cancer in Australia 1983–1985—where age standardisation used the
old World Standard Population. The NCSCH is able to provide State and Territory rates that
have been age standardised to the new WHO World Standard Population on request or State
and Territory cancer registries can be contacted directly.
Appendixes
The appendixes include the International Classification of Diseases 10th Revision coding
system; a methods section providing formulae, explanations and examples of the techniques
used to present the data in the report; population data for Australia for 1999; and a summary
table of State and Territory cancer registry characteristics.
This report, together with a comprehensive set of Excel tables for all cancer sites, is available
on the AIHW’s web site at www.aihw.gov.au/publications/.
72 Cancer in Australia
General
Excluding non-melanocytic skin cancers, there were 82,185 new cancer cases and 34,695
deaths due to cancer in Australia in 1999. At the incidence rates prevailing in 1999, it would
be expected that 1 in 3 men and 1 in 4 women would be directly affected by cancer in the
first 75 years of life. Further, an estimated 254,000 potential years of life would be lost to the
community each year as a result of people dying of cancer before the age of 75. Cancer
currently accounts for 29% of male deaths and 25% of female deaths.
In this publication the term ‘cancer site’ is used to represent cancers located in specific
organs or tissues as well as systemic cancers such as leukaemia and lymphoma.
Cancers not reported
Each year, approximately 270,000 new cancer cases of non-melanocytic skin cancer are
diagnosed in Australia. Incidence data for this cancer are not collected on a routine basis by
cancer registries. Estimates for the incidence numbers are derived from data collected by a
national market research company in 1985, 1990 and 1995, and analysis by Staples, Marks
and Giles (1998). In the 1995 survey, 63,745 people aged 14–95 years were interviewed about
treatment for skin cancer and there was follow-up with treating physicians for 63% of the
people who claimed to have had treatment for skin cancer in the last 12 months. Staples,
Marks and Giles produced estimated age-standardised incidence rates based on these survey
data for treated non-melanocytic skin cancers in 1995 of 1,374 per 100,000 population for
males and 857 per 100,000 population for females. These estimates were age standardised to
an older version of the World Standard Population and so are not directly comparable to
incidence estimates for other cancers published elsewhere in this report. However, if the
rates for other cancers based on 1999 data are recalculated using the older World Standard
Population, then the incidence rates for treated non-melanocytic skin cancers are 18 times the
next most common male cancer (prostate) and 11 times the next most common female cancer
(breast). Despite non-melanocytic skin cancer’s high incidence rate, it has a relatively low
mortality rate at 1.8 per 100,000 population for males and 0.5 per 100,000 for females
compared with the high mortality rates of male lung cancer at 33.4 per 100,000 population,
female breast cancer (17.2 per 100,000) and prostate cancer (15.6 per 100,000) (1999 data
standardised to the older World Standard Population).
Non-melanocytic skin cancer is excluded from any further comparisons in this publication.
The totality of other cancers is referred to as ‘registrable cancers’.
8Most common cancers
Persons
• Among all persons, the combination of cancers of the colon and rectum (11,637 new
cases), often referred to as bowel or colorectal cancer, is the most common registrable
cancer in 1999 (Table 1). Colorectal cancer, breast cancer (10,667), prostate cancer (10,232),
melanoma (8,243) and lung cancer (7,826) together account for 59% of all registrable
cancers in 1999.
Males
• In males, the most common registrable cancers after prostate cancer are colorectal cancer
(6,188 new cases diagnosed in 1999), lung cancer (5,275) and melanoma (4,627) (Table 1,
Figure 2). These four cancers account for 32% of all registrable cancers in males.
Females
• In females, breast cancer (10,592) is the most common registrable cancer, followed by
colorectal cancer (5,449), melanoma (3,616) and lung cancer (2,551), which in total
account for 27% of all registrable cancers in females.
Cancers causing death
• The cancers most commonly causing death are lung (4,645), prostate (2,512) and
colorectal (2,483) in males, and breast (2,512), lung (2,123) and colorectal (2,092) in
females (Table 1).
PYLL—person-years of life lost
The number of person-years of life lost due to cancer is generally dominated by the most
common cancers due to the large numbers of cases diagnosed, rather than by those less
common cancers which occur earlier in life. Lung cancer is responsible for the highest
number of person-years of life lost before 75 years of age (43,343 in 1999), followed by breast
cancer (29,953) and colorectal cancer (28,683) (Table 1). Cancer of the brain and nervous
system is responsible for the fourth highest number of person-years of life lost (16,160). This
contrasts with its ranking as the fourteenth most common cancer (1,348 new cases diagnosed
in 1999). Further, the ratio of person-years of life lost to new cases for cancer of the brain and
nervous system (12.0) is much higher than that for lung cancer (5.5), breast (2.8) or colorectal
cancer (2.5). This is a direct result of the relatively large number of younger people
diagnosed with, and dying from, cancer of the brain and nervous system.
The most common cancers by age
The most common cancers vary depending on age (Figure 3). In people aged less than 15, the
most common cancers diagnosed are lymphoid leukaemia and cancers of the brain and
central nervous system. These two cancer sites account for 45.3% of all cancers in this age
group. In those aged 15–44, melanoma and breast cancer are the most common cancers,
while breast, colorectal, melanoma, prostate and lung cancers are predominant in people
aged over 45 years.
9The ranking of the most frequently occurring cancers by age group (Figure 3) is based on the
number of new cases, and for those cancers the number of deaths is also shown. However,
some cancers that would be ranked in the top five cancers based on number of deaths (rather
than new cases) are not presented in Figure 2. Cancers which have a substantial number of
deaths in each age group that are not presented in Figure 2 are those of myeloid leukaemia
(12 deaths) in the 0–14 age group and cancer of the brain and nervous system (132) and
cancer of the lung (99) in the 15–44 age group. In the age group 45–64, cancers of unknown
primary site (466 deaths), cancer of the brain and nervous system (386), pancreatic cancer
(371), and non-Hodgkin’s lymphoma (355) are responsible for a substantial number of
deaths. Cancers of unknown primary site (1,990 deaths), cancer of the pancreas (1,303) and
non-Hodgkin’s lymphoma (1,058) are also significant causes of death in the 65 and over age
group.
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Table 1: Most frequently occurring cancers in Australia, 1999(a), (b)
New cases Deaths
Cancer site Number
% of all
new
cancer
cases
ASR
(A)
ASR
(W)
Lifetime
risk(c) Number
% of
all
cancer
deaths
ASR
(A)
ASR
(W) PYLL(c)
Males
Prostate 10,232 23.0 109.5 84.8 1 in 11 2,512 12.8 28.1 20.0 5,470
Colorectal 6,188 13.9 65.1 52.1 1 in 18 2,483 12.7 26.5 20.7 16,453
Lung 5,275 11.9 56.0 43.8 1 in 21 4,645 23.7 49.5 38.3 29,048
Melanoma 4,627 10.4 47.8 41.2 1 in 25 641 3.3 6.7 5.5 7,085
Bladder 2,076 4.7 22.2 17.2 1 in 60 602 3.1 6.7 4.9 2,180
NHL 1,775 4.0 18.5 15.5 1 in 67 793 4.0 8.4 6.6 7,048
Unknown site 1,585 3.6 17.0 13.2 1 in 81 1,248 6.4 13.5 10.3 7,745
Kidney 1,460 3.3 15.1 12.6 1 in 74 528 2.7 5.6 4.4 4,465
Stomach 1,301 2.9 13.8 10.9 1 in 91 754 3.8 8.1 6.3 5,288
Pancreas 916 2.1 9.7 7.7 1 in 129 868 4.4 9.3 7.2 6,055
All cancers 44,514 100.0 469.6 380.0 1 in 3 19,609 100.0 210.3 163.0 138,368
Females
Breast 10,592 28.1 97.7 87.7 1 in 11 2,512 16.7 22.0 18.9 29,685
Colorectal 5,449 14.5 47.0 38.0 1 in 26 2,092 13.9 17.1 13.4 12,230
Melanoma 3,616 9.6 34.2 30.8 1 in 35 364 2.4 3.2 2.7 4,370
Lung 2,551 6.8 22.6 18.4 1 in 48 2,123 14.1 18.6 14.8 14,295
Unknown site 1,505 4.0 12.4 9.8 1 in 110 1,298 8.6 10.3 8.0 7,065
NHL 1,487 3.9 13.1 10.9 1 in 92 710 4.7 6.0 4.7 4,973
Uterus 1,432 3.8 13.0 11.2 1 in 81 262 1.7 2.2 1.7 1,508
Ovary 1,173 3.1 10.6 9.3 1 in 107 731 4.8 6.3 5.1 5,948
Kidney 912 2.4 8.2 7.0 1 in 140 348 2.3 2.9 2.2 1,635
Pancreas 872 2.3 7.3 5.6 1 in 179 840 5.6 7.0 5.3 3,905
All cancers 37,671 100.0 339.2 291.1 1 in 4 15,086 100.0 127.4 102.3 115,825
Persons
Colorectal 11,637 14.2 55.3 44.6 1 in 22 4,575 13.2 21.3 16.7 28,683
Breast 10,667 13.0 51.0 45.3 1 in 22 2,533 7.3 11.8 10.0 29,953
Prostate 10,232 12.4 49.3 38.7 1 in 23 2,512 7.2 11.3 8.1 5,470
Melanoma 8,243 10.0 40.2 35.5 1 in 30 1,005 2.9 4.8 3.9 11,455
Lung 7,826 9.5 37.5 29.9 1 in 30 6,768 19.5 32.3 25.4 43,343
NHL 3,262 4.0 15.6 13.1 1 in 78 1,503 4.3 7.1 5.6 12,020
Unknown site 3,090 3.8 14.4 11.3 1 in 94 2,546 7.3 11.7 9.0 14,810
Bladder 2,805 3.4 13.2 10.3 1 in 95 859 2.5 3.9 2.9 2,970
Kidney 2,372 2.9 11.4 9.6 1 in 97 876 2.5 4.1 3.2 6,100
Stomach 1,962 2.4 9.3 7.3 1 in 133 1,205 3.5 5.6 4.4 7,798
All cancers 82,185 100.0 394.5 328.8 1 in 3 34,695 100.0 162.6 128.4 254,193
(a) Rates are expressed per 100,000 population and age standardised to the Australian 1991 Standard Population (ASR (A)) and to the World
Standard Population (ASR (W)). The rates age standardised to the two populations (World and Australia 1991) differ due to the age
distributions of these populations. For example, the World population gives more weight to younger age groups where there are fewer
cancers, and consequently the rate is lower compared with the Australian 1991 population. A greater weight is given to the older age
groups in the Australian 1991 population where there are more cancers, and consequently these rates tend to be higher.
(b) Non-melanocytic skin cancer, known to be the most common cancer type, is excluded from this list as it is not a registrable cancer.
(c) These measures are calculated for ages 0–74 years; PYLL refers to person-years of life lost. Methods for the calculation of these measures
are presented in Appendix B.
Note: NHL refers to non-Hodgkin’s lymphoma.
Source: Cancer in Australia 1999, AIHW & AACR, 2002.
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Most frequently occurring cancers
Note: NHL refers to non-Hodgkin’s lymphoma.
Source: Cancer in Australia 1999, AIHW & AACR, 2002.
Figure 2: Most frequently occurring cancers, Australia, 1999
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Most frequently occurring cancers by age group
Notes:
1. NHL refers to non-Hodgkin’s lymphoma. CNS refers to central nervous system.
2. Each age group is graphed on a different scale.
Source: Cancer in Australia 1999, AIHW & AACR, 2002.
Figure 3: Most frequently occurring cancers by age group, ranked by number of new cases
(persons), Australia, 1999
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Age and sex differences
Cancer occurs more commonly in males than females. The age-standardised incidence rate in
1999 for all cancers combined (excluding non-melanocytic skin cancers) was 469.6 new cases
per 100,000 for males and 339.2 per 100,000 for females, resulting in an age-adjusted sex ratio
of 1.4. Males have a higher incidence rate for every cancer site, except breast and for cancers
of the anus, gallbladder, thyroid and adrenal gland.
Of people diagnosed with cancer, 0.7% of all cancers (excluding non-melanocytic skin
cancers) occur in those aged less than 15 years, 9.9% in the 15–44 age group, 31.8% in the
45–64 age group, and 57.5% in those aged 65 and over. While the pattern of deaths across age
groups is similar to that of incidence, a larger proportion (72.2%) of cancer deaths occurs in
those aged 65 and over. Cervical and testicular cancers are exceptions to the age pattern,
with the number of cases in the 15–44 age group exceeding that in the 45–64 and 65 and over
age groups.
The risk of cancer increases with age. The age-specific incidence rate in 1999 for all cancers
combined (excluding non-melanocytic skin cancers) was 14.9 per 100,000 population for
people aged less than 15 years; 94.5 per 100,000 population for 15–44 year olds; 677.8 per
100,000 population for 45–64 year olds; and 2,142.9 per 100,000 population for people aged
65 years and over.
Age-specific incidence and mortality rates vary depending upon the cancer site (Figures 4–7).
For example, lung cancer incidence and mortality rates parallel each other closely from age
group 30–34, rising from ages 20–24 through to 75–79 (men) and from ages 20–24 through to
70–74 (women) before falling slightly in the oldest age groups. The age-specific incidence
rates for melanoma of the skin, on the other hand, rise much more steadily across the whole
age range. Some cancers, however, have their highest rates in early or middle life and remain
fairly constant in the higher age groups (for example, cancers of the breast and cervix) or
even decline with age (for example, cancer of the testis).
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Age-specific incidence and mortality rates—males
Note: Data for cancer of the testis have been averaged over 1995–1999 to provide more stable estimates.
Source: Cancer in Australia 1999, AIHW & AACR, 2002.
Figure 4: Age-specific incidence and mortality rates for melanoma and cancers of the lung, prostate
and testis in males, Australia, 1999
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Age-specific incidence and mortality rates—females
Source: Cancer in Australia 1999, AIHW & AACR, 2002.
Figure 5: Age-specific incidence and mortality rates for melanoma and cancers of the lung, breast
and cervix in females, Australia, 1999
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Age-specific incidence and mortality rates—males
Source: Cancer in Australia 1999, AIHW & AACR, 2002.
Figure 6: Age-specific incidence and mortality rates for colorectal cancer, cancers of the bladder and
stomach, and non-Hodgkin’s lymphoma in males, Australia, 1999
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Age-specific incidence and mortality rates—females
Source: Cancer in Australia 1999, AIHW & AACR, 2002.
Figure 7: Age-specific incidence and mortality rates for colorectal cancer, cancers of the uterus and
stomach, and non-Hodgkin’s lymphoma in females, Australia, 1999
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Alcohol- and smoking-related cancers 
Alcohol and smoking are risk factors for many cancers. In 1999, alcohol-related cancers 
accounted for 3.2% of all new cases of cancer, while smoking-related cases accounted for 
12.9% of all new cases of cancer. Smoking-related cases also accounted for a large proportion 
of deaths from cancer in 1999 (21.8% of all cancer deaths). These data and those in Tables 36 
and 37 are derived from a series of age- and sex-specific aetiological fractions developed by 
Ridolfo and Stevenson (2001) and from cancer incidence estimates for specific cancer sites for 
1999. These fractions are based on an analysis of international and Australian studies and 
estimate the probability that a specific agent (alcohol or tobacco) causes a specific disease 
(cancer). The cancers thought to be directly attributable to smoking (excluding passive 
smoking) and alcohol are listed in Table 2. 
Table 2: Cancer site and percentage of cancers attributable to alcohol and smoking 
Cancer site Males (%) Females (%) 
Alcohol-related cancers   
Oropharynx 38 28 
Oesophagus 45 36 
Liver 37 30 
Larynx 50 43 
Female breast cancer — 11 
Smoking-related cancers   
Oropharynx 52 41 
Oesophagus 51 41 
Stomach 12 9 
Anus 39 30 
Pancreas 23 17 
Larynx 68 59 
Lung 89 71 
Vulva — 32 
Penis 21 — 
Bladder 37 28 
Renal parenchyma 17 11 
Renal pelvis 51 42 
Note: In previous editions of Cancer in Australia, cancers of the uterus and cervix were included among smoking related cancers. However, more 
recent research has shown that this is not the case. 
Source: Ridolfo & Stevenson 2001. 
It is estimated that 2,602 new cases of cancer were directly attributable to alcohol 
consumption in 1999 at a rate of 13.7 cases per 100,000 population, as were 1,199 deaths at a 
rate of 6.3 per 100,000 population. While other cancers may be indirectly caused by alcohol 
consumption in combination with other risk factors, alcohol is believed to be the primary 
causative agent for differing proportions of specific cancers. The mechanism by which 
alcohol causes cancer has not been fully determined, but the major metabolite of ethanol has 
been shown to be carcinogenic in animal experiments (English et al. 1995). The lifetime risk 
of an alcohol-related cancer is 1 in 93 for males and 1 in 78 for females. Between 1990 and  
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1999, the incidence rate for alcohol-related cancers in males fell by an average of 0.3% per
annum, while the rate in females increased by 1.6% per annum.
Smoking-related cancers account for 17.3% of all new cases of cancer in males and 7.8% of all
new cases of cancer in females. This large difference is attributable to the higher rates of
smoking among men than women in the past 30 years. Twenty-five years ago smoking rates
in men were almost double those in women. This is no longer the case. In 1998, 25% of men
and 20% of women aged over 14 years were current smokers (AIHW 1999). Organs
associated with the respiratory system are the ones most affected by cigarette smoke, as a
result of the known carcinogens in cigarette smoke such as polycyclic aromatic hydrocarbons
(Table 2). Epidemiological evidence indicates that other cancers, including cancers of the
upper digestive tract, bladder, renal pelvis (kidneys) and pancreas are also associated with
cigarette smoking (English et al. 1995).
Cigarette smoking is estimated to have directly caused 10,619 new cases of cancer (55.9 new
cases per 100,000 population) and 7,554 deaths (39.8 per 100,000 population) in 1999.
Between 1990 and 1999, the male incidence rate for smoking-related cancers fell by an
average of 1.4% per year, while the rate for females rose by 0.8% per year. Over the same
period, mortality rates fell by 1.7% per annum for males and by 0.8% per annum for females
(Figure 11).
To illustrate the improvements in the male mortality rate for smoking-related cancers: if the
1989 age-specific rates were applied to the 1999 male population there would be an
additional 1,502 male deaths due to smoking in 1999. In contrast, the female mortality rate
for smoking-related cancers has increased since 1989. There would be 73 fewer female deaths
in 1999 if the 1989 rates were applied to the 1999 female population.
Cancer rates in the States and Territories, 1995–1999
Cancer incidence and mortality are reported here for the combined period 1995–1999 for all
States and Territories. Cancer registration is based on State and Territory of residency of the
patient at the time of diagnosis.
Melanoma rates
Cancer incidence is generally similar among States and Territories. However, variation in the
incidence of melanoma among States creates some differences in the overall incidence rates.
An analysis of all cancers combined (excluding non-melanocytic skin cancers) showed that
Queensland had the highest incidence in both males (508.9 per 100,000 population) and
females (360.9 per 100,000 population), while the Northern Territory reported the lowest
incidence with 429.5 cases per 100,000 for males and 313.9 per 100,000 for females (Figure 8,
Table 23).
Melanoma risk is generally highest in the northern areas and lower in the more southerly
areas, showing a correlation to exposure to ultraviolet radiation (Jelfs et al. 1994). Age-
standardised mortality ranges from 2.9 deaths per 100,000 population for the Northern
Territory to 5.8 deaths per 100,000 population for Queensland (Table 23).
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Incidence rates excluding melanoma
When the impact of melanoma was removed from the comparison, the order of States and
Territories with the highest and lowest cancer incidence rate for males changed with
Tasmania reporting the highest incidence rate for all cancers combined (excluding non-
melanocytic skin cancers and melanoma) among males (458.9 per 100,000 population), and
the Northern Territory reporting the lowest, with 397.0 cases per 100,000 population. The
remaining States and Territories reported the following rates for males: South Australia 449.6
per 100,000 population, Australian Capital Territory 449.1, Victoria 448.0, Queensland 443.2,
New South Wales 433.2 and Western Australia 418.6. For females, Victoria reported the
highest rate (316.9 per 100,000 population) and the Northern Territory reported the lowest
(292.9 per 100,000 population). The remaining States and Territories reported the following
rates for females: Tasmania 316.8, Queensland 313.8, South Australia 308.9, New South
Wales 303.1, Western Australia 296.3, and the Australian Capital Territory 295.1 per 100,000
population.
Mortality rates
The 1995–1999 cancer mortality rates reported for males across the States and Territories
range from 213.6 per 100,000 population in New South Wales to 235.2 per 100,000 population
in Tasmania. For females, the mortality rates vary from 129.4 per 100,000 population in New
South Wales to 173.6 in the Northern Territory (Table 18).
Lung cancer and smoking-related cancers
Lung cancer incidence rates are highest in the Northern Territory (for males 77.0 cases per
100,000 population, for females 38.3) (Table 22). The lowest lung cancer incidence rates are
reported for males in the Australian Capital Territory (39.9 per 100,000 population) and for
females in South Australia (21.8).
State and Territory variations in smoking-related cancers generally reflect those observed for
lung cancer (Table 37). The Northern Territory reported the highest incidence rates for males
and females (108.2 and 38.8 per 100,000 population respectively). The Australian Capital
Territory reported the lowest smoking-related cancer incidence rates for males (61.5 per
100,000 population) and South Australia had the lowest rate for females (24.2). Death rates
from smoking-related cancers were highest in the Northern Territory for both males and
females.
These patterns of incidence probably reflect smoking behaviour approximately 10–20 years
ago, due to the time lag between exposure to carcinogens in the tobacco smoke and the
diagnosis of cancer. Differentials in smoking rates between the States and Territories
reported in the 1995 National Health Survey (ABS 1997) are likely to affect smoking-related
cancer incidence rates in the future. Tasmania (57.3%) reported the highest proportion of
current and ex-smokers, followed by the Northern Territory with 56.0%. The lowest smoking
and ex-smoking rates were found in New South Wales at 49.2%. In the other States and the
Australian Capital Territory the proportions of smokers and ex-smokers ranged from 50% to
53%.
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Breast cancer and prostate cancer
Victoria reported the highest incidence rates for female breast cancer (101.2 per 100,000),
closely followed by South Australia, the Australian Capital Territory and Western Australia
(ranging from 100.9 to 100.4 cases per 100,000 population). The Northern Territory reported
the lowest incidence rate (72.7 cases per 100,000 population) (Table 24).
The Australian Capital Territory reported high rates of prostate cancer (163.7 per 100,000
population), while significantly lower rates were reported in the Northern Territory (84.5 per
100,000 population) (Table 28), a rate influenced by the low Indigenous population incidence
rates (d’Espaignet et al. 1996). These interstate variations in prostate cancer incidence might
also be explained by differences in the time and rate of uptake of prostate-specific antigen
(PSA) testing in the States and Territories (Smith, Armstrong & Saunders 1998; Threlfall,
English & Rouse 1998).
Cervical cancer
There were differences in cervical cancer incidence among the States and Territories. This
probably reflects in part the relative impact of the screening programs in each jurisdiction.
Most of the large States show consistent rates of approximately 8–10 new cases per 100,000
population; however, South Australia shows a substantially lower rate of 6.7 per 100,000
population (Table 25). The Northern Territory has a very high incidence rate of 16.1 per
100,000 population. A major contributor to this incidence rate is the high rate of cervical
cancer among the Indigenous population, which d’Espaignet et al. (1996) indicated was up to
three times the rate of the non-Indigenous population. This situation is also reflected in a
high mortality rate (8.1 deaths per 100,000 population). This high mortality rate may be an
indicator of late-stage detection of these cancers.
Explanations for variations
Differences in State and Territory cancer incidence rates may be explained by variations in
underlying cancer risk, the availability and utilisation of diagnostic procedures, reporting
and coding inconsistencies, and normal incidence rate fluctuations. A case in point is bladder
cancer (Table 30), where State and Territory comparisons vary by more than 100%. This is
largely due to differences in local coding practices, particularly in regard to the inclusion or
exclusion of tumours of uncertain behaviour. One of the main functions of the AACR is to
identify such differences in coding practice and agree on strategies to standardise coding and
produce comparable State and Territory data that are also comparable to published
international statistics.
Incidence rates for several types of cancer published in this report are considerably lower for
the Northern Territory than for other States. These differences are predominantly due to low
incidence of these cancers in Indigenous Australians, who comprise 29% of the Northern
Territory population (Condon J 2001). Incomplete case ascertainment also contributed to
these lower rates to a small extent. A review of data quality in the Northern Territory Cancer
Register undertaken during 2001 concluded that, compared to other Australian States, cancer
notification to the Northern Territory Cancer Registry in the period 1991–1999 was
approximately 6% incomplete (unpublished, J Condon). Under-ascertainment appeared to be
due to incomplete notification from one notification source and was not restricted to any
particular type of cancer.
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Care should be taken when interpreting incidence rates, especially for less common cancers
and for States and Territories with small populations. To reduce the problems of statistical
variation due to a small number of cases, the numbers and rates presented for the States and
Territories in Tables 18 to 37 in this publication are annual averages of the 5-year period
1995–1999. For annual sex- and cancer-specific data, or data cross-classified by other
variables (for example age, geographic area), the State and Territory cancer registries should
be contacted directly.
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All cancers and melanoma incidence rates by sex, States and Territories
                                       Source: Cancer in Australia 1999, AIHW & AACR, 2002.
                               Figure 8: Age-standardised incidence rates (95% confidence intervals)
                               for all cancers (excluding non-melanocytic skin cancers) and for melanoma,
                               States and Territories, 1995–1999
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3 Cancer trends
National trends in cancer incidence and mortality
National cancer incidence and mortality rates for the most common cancer sites are
presented in Figures 9–15. Incidence data are presented for the period 1983–1999 while
mortality data are presented for the period 1983–2000.
The trends in incidence and mortality rates vary with cancer site. Some rates have shown an
increase since 1983 while others have remained relatively stable or decreased. In assessing
these trends it is important to recognise that small changes in the trend in the most common
cancers (for example breast, prostate) can mean a substantial shift in the numbers of new
cases or deaths, whereas the same shift in less common cancers can have a relatively small
impact. For example, a 1% increase in the breast cancer incidence rate results in an increase
of approximately 106 new cases, whereas the same percentage increase in cervical cancer
incidence would result in approximately eight new cases.
Between 1990 and 1999, age-standardised incidence rates for all cancers combined (excluding
non-melanocytic skin cancers) rose for both males and females by an average of 0.3% and
0.8% respectively per year (Figure 9). These incidence rates have been strongly influenced by
the steady rise in breast cancer incidence and the rise and fall of prostate cancer incidence
during this period. Mortality rates declined for both males and females by an average of
1.1% and 1.0% respectively per year. The decline in male lung cancer and prostate cancer
deaths is the main contributor to the falling mortality rate for males.
                                Source: Cancer in Australia 1999, AIHW & AACR, 2002.
                          Figure 9: Trends in age-standardised incidence and mortality rates for all cancers
                          (excluding non-melanocytic skin cancers), Australia, 1983–2000
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Prostate cancer
Prostate cancer incidence rates were relatively stable up until 1989 but between 1990 and
1994 there was a dramatic rise in the number of new cases of prostate cancer registered
(Figure 10). This upward trend has been attributed to increased detection of the disease
through increased investigations, particularly the introduction of PSA testing (introduced
around 1990). However, from 1994 to 1997 the age-standardised prostate cancer incidence
rate fell by 30%. There was virtually no change between the 1998 and 1999 rate. PSA tests are
specifically designed to identify cancers before the onset of clinical symptoms. Many of these
prevalent cancers may not show any symptoms, and therefore would not be detected except
for PSA testing. Much of the rise in the incidence rate of prostate cancer can be attributed to
detection of these prevalent cancers. The recent decline in the incidence rate indicates a
return towards the underlying rate, removing the effect of these previously undetected cases.
The incidence rate is also declining as the number of PSA tests conducted falls, reducing the
number of prevalent cases detected (Smith, Armstrong & Saunders 1998; Threlfall, English &
Rouse 1998). The death rate from prostate cancer, which is significantly lower than the
incidence rate, decreased by 1.4% per annum between 1990 and 1999.
Breast cancer
Among females, breast cancer is the most frequently diagnosed cancer and it is the most
common cause of cancer-related death. The incidence of breast cancer in females rose from
83.5 cases per 100,000 population in 1990 to 97.7 cases per 100,000 population in 1999. The
breast cancer incidence rate increased on average 1.8% per annum between 1990 and 1999
(Figure 10). The increase in incidence in female breast cancer in the 50–69 year old age group
in 1993 and 1994 was most likely the result of the introduction of the national breast cancer
screening program, given that the 50–69 year olds were the main target age group. From
1990 to 1999 the breast cancer mortality rates declined by an average of 1.9% per year.
Colorectal cancer
For colorectal cancer, both the male and female incidence rates have increased since 1990 by
an average of 0.2 and 0.1% respectively per year while mortality rates have fallen steadily:
the male rate decreased 1.0% per annum between 1990 and 1999, the female rate decreased
1.4% (Figure 10).
Lung cancer
Between 1990 and 1999, the incidence and mortality of lung cancer among males fell by an
average of 1.9% and 1.8% respectively per year (Figure 11). These declining rates are
attributed to decreased tobacco smoking among men, and represent the lowest incidence
rate (56.0 new cases per 100,000 population) recorded since national data collection began in
1982. In contrast, lung cancer incidence among females increased by 1.0% per annum
between 1990 and 1999. However, the increase in lung cancer incidence is predominantly in
women aged 65 years and over, while rates in younger women have generally remained
stable or fallen. The death rate from lung cancer among females increased on average by
0.9% per annum between 1990 and 1999.
Melanoma
The incidence rate for melanoma among males and females increased between 1990 and 1999
on average by 2.5% and 1.6% per year respectively, some of this increase due to improved
registration of this cancer. Mortality rates for males increased by 0.2% per annum between
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1990 and 1999 while the female rates decreased by 0.7% per annum over the same period
(Figure 11).
Non-Hodgkin’s lymphoma
The incidence of non-Hodgkin’s lymphoma increased by an average of 0.6% per year in
males and 1.6% in females between 1990 and 1990 (Figure 12). The mortality rate in males
with non-Hodgkin’s lymphoma declined by 0.3% annually between 1990 and 1999. The
female mortality rate increased on average 1.2% per annum between 1990 and 1999.
Cancer of the bladder
The incidence of bladder cancer for males increased between 1990 and 1999 by an average of
0.3% per annum (Figure 12). It is likely that part of an increase in male incidence is a result of
the increased use of screening for prostate cancer leading to a diagnosis of bladder cancer as
part of the diagnostic work-up. The female incidence rate increased by an average of 1.1%
per annum over the same period. Mortality rates decreased for both males and females
between 1990 and 1999—0.5% per annum and 1.3%per annum respectively.
Cancer of the stomach
Stomach cancer incidence fell by an average of 2.1% and 1.6% per year for males and females
respectively over the period 1990–1999 (Figure 12). Mortality rates decreased substantially
for both sexes over the 1990 to 1999 period by 3.2% in males and 3.4% in females on average
per annum.
Leukaemias
The incidence rate for leukaemias in males decreased between 1990 and 1999 by an average
of 1.1% per year (Figure 13). The incidence for females remained stable over the same period.
During the same time the mortality rates decreased by 0.2% per annum for males and by
0.7% per annum for females.
Brain cancer
Incidence of brain cancer between 1990 and 1999 increased in males by an average of 0.2%
per annum and decreased in females by an average of 1.0% per annum (Figure 13). The
mortality rate over the same period decreased on average for both males and females by
0.3% and 1.1% respectively per year.
Cancer of the pancreas
Between 1990 and 1999, the male incidence and mortality rates for cancer of the pancreas fell
annually by an average of 0.8% and 0.5% respectively. In contrast, over the same period, the
female incidence rate increased by an average of 0.6% per year and the female mortality rate
increased by an average of 0.3% per year (Figure 13).
Cervical cancer
The age-standardised incidence rate for cervical cancer declined by an average of 5.4% per
annum between 1990 and 1999 (Figure 14). This decline was achieved despite a sharp rise in
new cases between 1993 and 1994 and between 1997 and 1998. Mortality rates have fallen by
an average of 5.5% per year since 1990. These gains are due, in part, to the success of the
National Cervical Screening Program.
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Cancer of the uterus
The incidence rates for cancer of the uterus increased on average by 0.5% between 1990 and
1999. Mortality rates decreased 1.0% per annum in the same period (Figure 14).
Cancer of the ovary
The incidence and mortality rates for cancer of the ovary declined on average by 0.3% and
1.7% per year between 1990 and 1999 respectively (Figure 14).
Cancer of the kidney
Between 1990 and 1999, male and female incidence rates for cancer of the kidney increased
by an average of 1.7% and 1.2% per annum respectively. Male mortality rates increased
marginally by 0.2% while female rates declined by 1.0% per annum (Figure 15).
Cancer of the testis
The incidence rates for testicular cancer increased on average by 2.5% per annum between
1990 and 1999. The mortality rates declined on average by 1.2% per annum over the same
period (Figure 15).
Cancers of unknown primary site
‘Cancers of unknown primary site’ is a category that captures cancer diagnoses which cannot
be attributed to a particular body site. While some of these cancers have common features, at
least in terms of aetiology, behaviour and outcome, others are a mixed collection. This makes
it difficult to interpret with certainty the patterns of these cancers, particularly for mortality
where often little histological evidence is available to identify a cancer site. Although there
are many cancers in this category, it is important to know the current trends, given that this
cancer group represents about 4% of new cases and 7% of deaths. Between 1990 and 1999
mortality rates declined for both males and females on average by 1.6% and 1.1% per annum
respectively (Figure 15). This may reflect a tendency for clinicians to investigate cancer cases
more extensively, or for patients to present earlier with symptoms, before further
investigation becomes unfruitful, resulting in fewer cases being classified as cancers of
unknown primary site.
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Cancers of the prostate and breast, and colorectal cancer
                         Source: Cancer in Australia 1999, AIHW & AACR, 2002.
                    Figure 10: Trends in age-standardised incidence and mortality rates for cancers
                    of the prostate and breast, and colorectal cancer, Australia, 1983–2000
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Cancer of the lung, smoking-related cancers and melanoma
                        Note: Melanoma is graphed on a different scale from cancer of the lung and smoking-related cancers.
                       Source: Cancer in Australia 1999, AIHW & AACR, 2002.
                   Figure 11: Trends in age-standardised incidence and mortality rates for cancers
                   of the lung, smoking-related cancers and melanoma, Australia, 1983–2000
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Non-Hodgkin’s lymphoma, and cancers of the bladder and stomach
                         Source: Cancer in Australia 1999, AIHW & AACR, 2002.
                    Figure 12: Trends in age-standardised incidence and mortality rates for non-Hodgkin’s
                    lymphoma, and cancers of the bladder and stomach, Australia, 1983–2000
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Leukaemias, and cancers of the brain and pancreas
                           Source: Cancer in Australia 1999, AIHW & AACR, 2002.
                     Figure 13: Trends in age-standardised incidence and mortality rates for leukaemia
                     and cancers of the brain and pancreas, Australia, 1983–2000
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Cancers of the cervix, uterus and ovary
                           Source: Cancer in Australia 1999, AIHW & AACR, 2002.
                      Figure 14: Trends in age-standardised incidence and mortality rates for cancers of
                      the cervix, uterus and ovary, Australia, 1983–2000
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Cancers of the kidney and testis, and cancers of unknown primary site
                             Note: Cancers of unknown primary site are graphed on a different scale from cancers of the kidney and testis.
                             Source: Cancer in Australia 1999, AIHW & AACR, 2002.
                       Figure 15: Trends in age-standardised incidence and mortality rates
                       for cancers of the kidney and testis, and cancers of unknown primary site,
                       Australia, 1983–2000
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4 Incidence and mortality
tables
Guide to interpreting incidence and mortality tables
This section provides information to assist in the interpretation of the tables in this report.
More detailed information on methods is given in Appendix B.
Table features
• Tables are ordered according to the International Classification of Diseases, 10th
Revision.
• All rates are presented per 100,000 population.
• Age-standardised rates are calculated by the ‘direct method’ (see definition in
Appendix B). Age-standardised rates for Australia use both the total 1991 Australian
population and the new WHO World Standard Population as the standard populations.
Age-standardised rates for the States and Territories use only the total 1991 Australian
population as the standard population. Therefore, particular care should be taken not to
compare these State and Territory rates with previous Cancer Series publications—
Cancer in Australia 1989–1990 (with Projections to 1995), Cancer in Australia 1986–1988
or Cancer in Australia 1983–1985—where age standardisation used the old World
Standard Population.
• The person-years of life lost (PYLL) and lifetime risk estimates are for the ages
0–74 years.
• The confidence intervals used for crude and age-standardised rates are at the 95% level.
• The ‘all cancers’ incidence and mortality estimates exclude non-melanocytic skin cancers.
• In this publication the term ‘cancer site’ is used to represent cancers located in specific
organs or tissues as well as systemic cancers such as leukaemia and lymphoma.
• In this publication the term ‘melanoma’ refers to melanoma of the skin only. Melanomas
generally occur on the skin, but may also occur on the eye and mucous membranes (such
as the vaginal and nasal cavities).
Comparison of rates
Care should be exercised when interpreting a comparison between incidence or mortality
rates—for example, when comparing different cancers or when comparing the same cancer
in different years. The confidence intervals indicate the likely range of fluctuation of each
rate. Some fluctuations may be within expectations, while others may indicate a change in
the patterns of cancer incidence or mortality. Where small annual numbers of cancer cases or
deaths are presented in a table, a direct comparison may produce a false perception of
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dramatic changes over time and, in these instances, averages over a period of time should be
used. In general, cancer incidence and mortality rates change relatively slowly over time,
although from year to year there may be marked fluctuations due to significant changes in
diagnostic procedures. Changes over the longer term may also reflect changing exposures to
risk factors.
Combining rates
• Age-specific rates may be summed over cancer sites for a particular age and sex.
• Age-specific rates may not be summed across different ages or sexes, but should be
recalculated from the raw data. However, if populations are similar, the crude rates for a
10-year age group will be approximated by the average of the two 5-year age-specific
rates. For comparison within broader age groups, summary rates should be age
standardised.
State and Territory data
In August 2002 cancer incidence data were available to 1999 for all States and Territories, and
to 2000 for New South Wales, the Australian Capital Territory, South Australia, Western
Australia, the Northern Territory and Queensland.
The Australian data are presented as annual numbers and rates, while the data for each State
and Territory are presented as average annual rates and numbers of cases and deaths based
on the 5-year average 1995–1999. By presenting the data in this manner, natural statistical
variation due to small numbers of cases or deaths within each State and Territory and cancer
site are averaged across the period and provide a more stable and representative rate of
incidence or mortality. Nonetheless, care should be taken in the interpretation of these rates,
especially for less common cancers or for States and Territories with small populations.
All average numbers of cases or deaths per year in the State and Territory tables are rounded
to the nearest integer. Occasionally, the number of cases or deaths will be zero but a small
corresponding rate will appear. This indicates that there were, on average, fewer than 0.5
cases or deaths per year over the 5-year period and, although the rounding process has made
the entry zero, a rate can still be presented at one decimal point.
The data in this report will not correspond exactly to data published by the individual State
and Territory cancer registries due to the 5-year annual averaging, the use of different
standard populations for age standardisation and the continual updating of data sets by the
cancer registries.
In this report, State and Territory incidence and mortality rates have been directly age
standardised to the total estimated resident population of Australia at 30 June 1991. Care
should be taken not to compare these State and Territory age-standardised rates with
previous Cancer Series publications—Cancer in Australia 1989–1990 (with Projections to 1995),
Cancer in Australia 1986–1988 or Cancer in Australia 1983–1985—where age standardisation
was done using the old World Standard Population. However, the NCSCH is able to provide
State and Territory rates that have been age standardised to the new WHO World Standard
Population on request or the registries can be contacted directly.
Cancer incidence estimates provided in this publication were made at August 2002. These
estimates may be updated at any time as case details are added, modified or deleted in the
national database. These modifications may occur several years after the initial diagnosis as
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additional case details are received by the State and Territory cancer registries from data
suppliers and then passed to the NCSCH. This may have the impact of making incidence
estimates for the same year incompatible between publications, but for the most part these
changes are very small.
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5 Other sources of cancer data
Cancer mortality—multiple causes of death
The mortality data reported in the summary tables in this report relate to deaths where
cancer was recorded as the underlying cause of death. However, a diagnosis of cancer can
raise a person’s risk of death from a number of associated causes and these deaths may not
be coded as having cancer as their underlying cause. Since 1997, national deaths data in
Australia have been compiled with multiple causes of deaths. Multiple causes of death
include all causes and conditions recorded on the death certificate (that is, both underlying
and associated). The following table lists the National Health Priority Area cancers and
shows the number of underlying and associated causes appearing on death certificates for
deaths registered in 1999. For example, in Australia in 1999 there were 35,053 deaths where
the underlying cause was malignant cancer and 11,714 additional deaths where cancer was
the associated cause reported on the death certificate.
Table 3: Number of persons dying with cancer from another cause of death, Australia, 1999 (year of
registration)
Cancer Underlying cause
Additional persons who
died with this cancer Total
All malignant cancers (C00–C97) 35,053 11,714 46,767
Colorectal cancer (C18–C21) 4,576 556 5,132
Lung (C33–C34) 6,803 466 7,269
Melanoma (C43) 990 131 1,121
Non-melanocytic skin cancer (C44) 381 152 533
Breast (C50) 2,527 504 3,031
Cervix (C53) 220 48 268
Prostate cancer (C61) 2,499 1,150 3,649
Non-Hodgkin's lymphoma
(C82–C85, C96) 1,496 259 1,755
Sources: ABS 2000b; AIHW Mortality Database.
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Survival following cancer diagnosis
Survival after a diagnosis of cancer is an important measure in assessing the broad impacts
of prevention, of early detection methods such as screening, and of treatment. Relative
survival is the method commonly used by population-based cancer registries to measure and
assess survival. It is the ratio between what actually happened to a group of people with
cancer and what would normally have occurred to them in the absence of cancer. This
discussion will focus on the 5-year relative survival proportion. This is the relative survival
over the first 5-years following a diagnosis of cancer. A relative survival of 100% indicates
that the disease has made no difference to survival of the group over this period. A survival
rate of less than 100% indicates that fewer members of the group survived for 5-years than
would have been expected for similar people in the general population.
The average 5-year relative survival proportion for all registrable cancers diagnosed in
Australia between 1992 and 1997 was 56.8% for males and 63.4% for females (Tables 4 and 5).
Table 4: Five-year relative survival ratios for all registrable
cancers and selected individual cancer sites, diagnosis
period, males, Australia
Diagnosis period
Cancer site 1982–1986 1987–1991 1992–1997
Males (Per cent)
Testis 91.1 95.2 95.4 *
Melanoma 83.0 87.2 90.0 *
Thyroid 81.0 82.6 87.9
Prostate 59.3 64.3 82.7 *
Hodgkin’s lymphoma 74.1 79.1 82.6 *
Bladder 71.2 71.6 70.8
Kidney 50.8 53.7 59.9 *
Colon 50.2 54.7 58.3 *
Rectum 48.7 51.2 56.6 *
Non-Hodgkin’s lymphoma 49.6 51.1 54.6 *
Leukaemia 39.4 43.3 41.2
Brain 24.8 24.3 23.8
Stomach 19.2 21.6 22.6 *
Unknown primary 11.7 13.0 13.4
Lung 9.3 10.7 11.0 *
Pancreas 4.2 4.4 5.4
All registrable cancers 43.8 48.1 56.8 *
* Change between 1982–1986 and 1992–1997 is statistically significant at the 95% level.
Source: AIHW & AACR 2001.
The cancers with the highest relative survival in males were cancer of the testis (95.4%) and
melanoma (90.0%) and in females were cancer of the thyroid (95.6%) and melanoma (94.6%).
Cancers with the lowest relative survival in males were cancer of the pancreas (5.4%), and
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cancer of the lung (11.0%) and in females were cancer of the pancreas (5.2%) and cancers of
unknown primary site (11.5%).
Table 5: Five-year relative survival proportions for all
registrable cancers and selected individual cancer sites and
diagnosis period, females, Australia
Diagnosis period
Cancer site 1982–1986 1987–1991 1992–1997
Females (Per cent)
Thyroid 87.8 91.9 95.6 *
Melanoma 90.9 93.5 94.6 *
Hodgkin’s lymphoma 73.8 79.9 84.4 *
Breast 72.3 77.8 84.0 *
Uterus 76.1 78.5 81.4 *
Cervix 69.6 72.0 74.6 *
Bladder 67.2 65.2 64.7
Rectum 52.3 56.0 60.6 *
Colon 51.3 54.7 58.7 *
Kidney 49.4 52.7 57.5 *
Non-Hodgkin’s lymphoma 49.9 54.6 55.8 *
Leukaemia 39.4 44.2 43.2 *
Ovary 34.4 37.7 42.0 *
Stomach 21.1 21.8 24.8 *
Brain 24.1 25.3 23.8
Lung 11.8 11.9 14.0 *
Unknown primary 10.4 10.9 11.5
Pancreas 4.1 5.4 5.2
All registrable cancers 55.3 59.1 63.4 *
* Change between 1982–1986 and 1992–1997 is statistically significant at the 95% level.
Source: AIHW & AACR 2001.
Five-year relative survival for all registrable cancers increased between 1982–1986 and
1992–1997 on average from 43.8% to 56.8% for males and from 55.3% to 63.4% for females.
Most individual cancer sites showed an increase in relative survival over this period. The
largest increases for males were in cancer of the prostate (59.3% to 82.7%) and cancer of the
kidney (50.8% to 59.9%) and for females were in cancer of the breast (72.3% to 84.0%) and
Hodgkin’s lymphoma (73.8% to 84.4%). Cancers of the brain and bladder showed small
decreases in relative survival over this period for both males and females, but these
decreases were not statistically significant.
For registrable cancers diagnosed in males during the period 1992–1997, relative survival in
capital cities, other metropolitan areas and large rural centres was close to 57.5%. This was
significantly above the proportions in other areas, which ranged from 55.2% for small rural
centres to 51.9% for ‘other remote’ areas (Table 6).
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There were no statistically significant differences in relative survival for females between
metropolitan, rural and remote areas. Five-year relative survival was highest in large rural
centres (64.2%) and lowest in ‘other remote’ areas (61.9%).
Table 6: All cancers 5-year relative survival
proportions, geographic location and sex,
Australia, 1992–1997
Location Males Females
(Per cent)
Capital cities 57.5 63.6
Other metropolitan 57.4 62.6
Large rural centres 57.6 64.2
Small rural centres 55.2 63.0
Other rural areas 54.7 62.2
Remote centres 52.7 63.0
Other remote areas 51.9 61.9
Source: AIHW & AACR 2001.
Better off Australians tend to have better cancer survival. Five-year relative survival for both
males and females, according to their socioeconomic status as measured by the ABS Index of
Relative Socioeconomic Disadvantage, increased from the lowest quintile (most
disadvantaged) through to the highest (least disadvantaged). For males diagnosed during
the period 1992–1997, relative survival was 51.9% for persons resident in the most
disadvantaged areas of Australia, and 61.4% for residents of the most advantaged areas. For
females, there was a lesser disparity, with a relative survival of 61.9% in the bottom quintile
and 63.4% in the highest. This may be partly attributed to higher rates of breast cancer in
women living in higher socioeconomic status areas (Table 7).
Table 7: All cancers 5-year relative survival
proportions, socioeconomic status and sex,
1992–1997
Quintile of socioeconomic status Males Females
(Per cent)
1 (highest) 61.4 63.4
2 57.0 62.3
3 55.6 61.0
4 55.2 60.9
5 (lowest) 54.3 60.4
Source: AIHW & AACR 2001.
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Risk factors
In the cancer context, a risk factor is any feature or exposure that represents a greater risk of
developing cancer. Risk factors can be categorised as person-related, individual and
physiological risk factors (for example, genetic predisposition, sex, age, high blood pressure,
raised cholesterol levels), behavioural risk factors (for example, smoking, physical inactivity,
high fat diet), environmental, socioeconomic factors, and community capacity factors. Some
risk factors are modifiable through lifestyle changes. This chapter focuses on key modifiable
risk factors for which data are available. These are discussed, and where data are available,
trends in prevalence are shown.
Significant modifiable behavioural risk factors that have been shown to cause cancers are
tobacco smoking, poor diet, excessive sun exposure, alcohol abuse, physical inactivity and
obesity. While these risk factors are the most significant, there are a range of other factors
that are related to specific cancers but only contribute a small proportion of the overall
explanation of cancer, for example, asbestos and mesothelioma. Some of these risk factors act
independently to cause cancers but they can also work together to increase risk.
Not all cancers are the same and are affected by these risk factors in different ways. For
example, tobacco smoking has been shown to have a very strong association with cancers of
the respiratory system (for example, lung); however, it plays a smaller role in other cancers
such as cancer of the cervix.
Tobacco smoking
Tobacco smoking is the single most preventable cause of cancer and cancer deaths. Direct
smoking alone is estimated to be responsible for one-fifth of all cancer deaths in Australia
and kills almost 7,000 Australians per year (AIHW 2002a). It is considered to be responsible
for 90% of lung cancer deaths (Peto et al. 2000). As well as being the leading cause of lung
cancer death in both men and women, smoking is linked to cancers of the larynx,
oropharynx, renal (kidney) pelvis, oesophagus, anus, bladder, vulva, penis, renal
parenchyma, pancreas and cervix (Cancer Council of Australia 2001; Ridolfo & Stevenson
2001; English et al. 1995).
In Australia, smoking rates have been declining since the 1950s, when it was estimated that
around 70% of males and 30% of females smoked. Since 1985, smoking rates have continued
to decline and, in 2001, fell below 20% for the first time (Figure 16).
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Note: Includes people aged 14 years and over.
Source: AIHW 2002a.
Figure 16: Proportion of people who are daily smokers, 1985–2001
Nutrition
Evidence is building that a diet rich in fruit and vegetables, wholegrain cereals, starch and
calcium while at the same time limiting the intake of fats, salt and sugar, may reduce the risk
of developing cancers (AIHW 2002a). Cancers that have been linked to diet are those of the
nasopharynx, stomach, liver, colon, rectum and breast (Cancer Council of Australia 2001).
The decrease in deaths associated with colorectal cancer is largely attributed to
improvements in diet such as consuming less fat, more cereals and vegetables and reduced
alcohol consumption (AIHW 2000a).
Alcohol consumption
Alcohol consumption is known to be a contributing cause of cancers of the liver, laryngeal,
oropharyngeal, oesophagus, and the female breast (Ridolfo & Stevenson 2001). It is estimated
that 2,602 new cases of cancer  and 1,199 deaths from cancer were directly attributable to
alcohol consumption in 1999.
Australia’s drinking pattern has remained largely unchanged over the last decade
(Figure 17). In 2001, around 48% of the population aged 14 years and over consumed alcohol
on at least one day per week. A further 35% consumed alcohol less than once per week, and
the remaining 17% either no longer drank alcohol or had never consumed a full glass of
alcohol.
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Note: Includes people aged 14 years and over.
Source: Australia’s Health 2002 from National Drug Strategy Household Survey.
Figure 17: Alcohol drinking status, 1991–2001
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Screening
Breast, cervical and bowel cancers are three of a small group of cancers where there is
evidence that illness and death can be reduced through population-based screening and
effective follow-up treatment. National screening programs for breast cancer (via
mammography) and cervical cancer (via Pap smears) have been implemented in Australia
with the aim of achieving this reduction. These programs are called BreastScreen Australia
and the National Cervical Screening Program. Pilot tests for a population-based screening
program for bowel cancer are currently being developed, with pilot test screening expected
to commence in late 2002.
BreastScreen Australia
The BreastScreen Australia program is jointly funded by the Commonwealth and State and
Territory governments. It consists of a network of dedicated screening and assessment
services throughout metropolitan, rural and remote areas of all Australian States and
Territories. These services can be fixed or mobile and provide free biennial mammographic
screening and follow-up of any suspicious lesions identified at screening to the point of
diagnosis of breast cancer. The program is aimed specifically at women aged 50–69 years of
age without symptoms, although women aged 40–49 years and 70 years and older may
attend for screening. Women may attend without a doctor’s referral.
Recruitment and reminder systems are used to promote screening and re-screening among
women in the target group once every 2 years.
A comprehensive system of accreditation is used to ensure that all BreastScreen Australia
services operate under a common set of standards. Each service is assessed on a regular basis
by an independent team to ensure that the service provided complies with national
standards.
The proportion of women in the target age group who were screened under the BreastScreen
Australia program in a 2-year period rose from 51.4% in the period 1996–1997 to 55.9% in the
period 1998–1999 (Table 8).
Table 8: Number of women screened by BreastScreen Australia in each 2-year period, 1996–1999
1996–1997 1997–1998 1998–1999
BreastScreen Australia
Ages 40 years and over 1,240,885 1,367,759 1,452,263
Target population (ages 50–69 years) 844,607 921,283 975,258
Participation rate for target population (%) 51.4 54.3 55.9
Note: Participation rates are age-standardised to the 1991 total Australian population.
Source: AIHW analysis of BreastScreen Australia data.
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Source: AIHW analysis of BreastScreen Australia data.
Figure 18: Participation of women aged 50–69 years in BreastScreen Australia by region, 1998–1999
Source: AIHW analysis of BreastScreen Australia data.
Figure 19: Participation of women aged 50–69 years in BreastScreen Australia by socioeconomic
status, 1998–1999
Participation rates in 1998–1999 in non-capital city metropolitan areas, large and small rural
centres, other rural areas and remote centres were all statistically significantly higher than
the rates for capital cities and other remote areas (Figure 18). These higher rates reflect
policies aimed at encouraging participation in country areas, for example, through the use of
mobile mammography units. There was no consistent pattern in participation rates by
relative socioeconomic disadvantage, with no statistically significant difference in
participation between the most and the least disadvantaged groups (AIHW 2002a).
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National Cervical Screening Program
Screening to detect abnormalities of the cervix has been available for Australian women
since the 1960s. Until the early 1990s this screening was largely unstructured, with no
agreement on the screening target group or the best interval between screens. Since then it
has become progressively more organised and in 1995 the program became known as the
National Cervical Screening Program.
Unlike breast screening, cervical screening in Australia does not operate through a separate
dedicated screening and assessment service. Instead, screening services are provided as part
of mainstream health services, with approximately 80% of Pap smears performed by general
practitioners. Cervical screening is funded mainly by Medicare (61%) with the remainder
funded by Commonwealth government contributions through special purpose payments to
State and Territory governments (23%) and these governments’ own revenue sources (16%).
The National Cervical Screening Program has both national and State and Territory
components. Although policy is usually decided at a national level, coordination of
screening activity mainly happens at a State and Territory level.
Cervical cytology registries operate in all States and Territories. The major functions of the
registries are to:
• remind women to attend for screening
• ensure the follow-up of women with abnormal Pap smears
• provide cervical screening histories to laboratories and clinicians to aid reporting and
management
• monitor the effects of initiatives to improve participation by women in screening.
The current Australian recommendation is for all women who have been sexually active at
any stage in their lives to have a Pap smear every 2 years until they reach the age of 70 years.
Screening may cease at the age of 70 for women who have had two normal Pap smears
within the last 5 years. Women over 70 years who have never had a Pap smear or who
request a Pap smear are also screened. However, for reporting purposes the target group is
taken to be all women aged between 20 and 69 years who have not had a hysterectomy.
The proportion of women in the target age group who were screened under the National
Cervical Cancer Screening Program in a 2-year period rose from 62.3% in the period
1996–1997 to 64.8% in the period 1998–1999 (Table 9).
Table 9: Number of women screened by the National Cervical Screening Program in each 2-year
period, 1996–1999
1996–1997 1997–1998 1998–1999
National Cervical Screening Program
Ages 20 years and over 2,630,235 2,721,650 2,777,324
Target population (ages 20–69 years) 2,563,108 2,653,504 2,716,364
Participation rate for target population (%) 62.3 63.9 64.8
Notes
1. Participation rates are age standardised to the 1991 total Australian population.
2. The Queensland Health Pap Smear registry only commenced in February 1999. Hence the data presented here for cervical screening
exclude screening in Queensland.
Source: AIHW analysis of State and Territory Cervical Cytology Registry data.
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Hospital inpatients with cancer
The Australian Institute of Health and Welfare (AIHW) National Hospital Morbidity
Database (NHMD) contains diagnosis and treatment information for inpatients in almost all
public and private hospitals in Australia from 1993–94 to 2000–01. AIHW publishes detailed
statistics on these in June each year for inpatient separations for the previous financial year.
The most recent report is for 2000–01 (AIHW 2002).
The NHMD contains a wealth of data and many variables, with many interrelationships.
This chapter presents summary data for admitted patients for whom one of the National
Health Priority Area cancers was their principal diagnosis in 2000–01.
Principal diagnosis
The principal diagnosis is defined as the diagnosis established, after study, to be chiefly
responsible for occasioning the admitted patient’s episode of care in hospital. Principal
diagnoses for 2000–01 were classified, coded and reported to the National Hospital
Morbidity database by all States and Territories using the second edition of the International
Statistical Classification of Diseases and Related Health Problems, 10th Revision, Australian
Modification (ICD-10-AM) (NCCH 2000).
Same-day patients
In 2000–01, 85% of separations where the patient underwent chemotherapy administration
were on a same-day basis. Reporting average length of stay (ALOS) based upon all patient
separations may be biased if same-day patients are included; therefore the ALOS has been
reported excluding same-day stays.
In the financial year 2000–01 there were 306,536 hospital separations where cancer was
recorded as the principal diagnosis. This represents 5.0% of all separations in that year.
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Interrelationships for diagnoses of National Health Priority Area
cancers
Colorectal cancer—ICD-10-AM C18–C21
Figure 20 presents the interrelationships with various data elements where the principal
diagnosis was colorectal cancer. Colorectal cancer includes Malignant neoplasm of colon (C18),
Malignant neoplasm of rectosigmoid junction (C19), Malignant neoplasm of rectum (C20) and
Malignant neoplasm of anus and anal canal (C21).
There were 25,238 separations where colorectal cancer was recorded as the principal
diagnosis. Of these, 7,360 (29%) were same-day patients. For non-same-day patients, the
average length of stay was 11.7 days. Other key points from the figure are:
• 53% of separations were in the public sector.
• 46% of separations were for public patients.
• 55% of separations were for males.
• The 65–74 years age group had the largest number of separations (30%).
• The majority of patients (93%) had acute care and 6% had palliative care.
• A large proportion of patients (83%) had a separation mode of Other, indicating that
these patients went home after separation from hospital, whereas 8% had a separation
mode of Died.
• The most common diagnosis in addition to a principal diagnosis of colorectal cancer was
Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes (C77.2).
• The most common surgical procedure performed was Fibreoptic Colonoscopy with excision
(Block 911).
• The most commonly reported AR-DRG was Other Colonoscopy, Sameday (AR-DRG G44C).
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Additional diagnoses (top 10)  State or Territory AR-DRGs (top 10)
C77.2 Secondary and unspecified malignant neoplasm of 4,089 NSW 4,644 G44C Other Colonoscopy, Sameday 4,444
intra-abdominal lymph nodes VIC 3,561 G02B Major Small and Large Bowel Procedures W/O Cat CC 3,591
C78.7 Secondary malignant neoplasm of liver 3,945 QLD 2,011 G60B Digestive Malignancy W/O Catastrophic or Severe CC 3,436
Z86.43 Personal  history of tobacco use disorder 2,733 WA 1,062 G60A Digestive Malignancy W Catastrophic or Severe CC 3,274
I10 Essential (primary) hypertension 2,641 SA 1,392 G01B Rectal Resection W/O Catastrophic CC 2,982
K57.30 Diverticulosis of large intestine without perforation, abscess 1,813 TAS 275 G02A Major Small and Large Bowel Procedures W Cat CC 2,389
or mention of haemorrhage ACT 274 G01A Rectal Resection W Catastrophic CC 1,607
E11.9 Type 2 diabetes mellitus without complication 1,712 NT 38 G42B Other Gastroscopy for Major Digestive Disease, 1,025
Z51.5 Palliative care 1,701 Sameday
Z72.0 Tobacco use, current 1,672 G44B Other Colonoscopy W/O Catastrophic or Severe CC 551
D63.0 Anaemia in neoplastic disease 1,607 or Complicating Procedure
K63.5 Polyp of colon 1,321 G42A Other Gastroscopy for Major Digestive Disease 503
Care type
Medicare eligibility and funding source Acute 23,401
Medicare eligible 25,022 PRINCIPAL DIAGNOSIS Rehab 8
Public 11,611 Sector C18–C21 Colorectal cancer Palliative 1,447
Private 13,411 Public 13,257 Separations 25,238 Geriatric evaluation 57
    Compensable 64 Private 11,981 Patient days 217,421 Psychogeriatric 39
    Dept of Veterans' Affairs 2,263 ALOS (days) 11.7  Sex Maintenance 42
    Other private 11,084  Male 13,925 Newborn 0
Not Medicare eligible 37  Female 11,313 Other care 46
Not reported 179 Not reported 198
Procedure block (top 10)  Age group Separation mode
1910 General anaesthesia 12,574 0–4 1 Discharge/transfer to an(other)acute hospital 1,325
1916 Generalised allied health interventions 10,531 5–14 3 Discharge/transfer to a residential aged care service 211
911 Fibreoptic colonoscopy wi th excision 6,946 15–24 39 Discharge/transfer to an(other) psychiatric hospital 1
1911 Sedation 6,309 25–34 215 Discharge/transfer to other health care accommodation 78
913 Colectomy 5,824 35–44 862 Statistical discharge—type change 506
1893 Transfusion of blood and gamma globulin 4,328 45–54 2,653 Left against medical advice 32
933 Anterior resection of rectum 3,363 55–64 5,484 Statistical discharge from leave 25
905 Fibreoptic colonoscopy 1,840 65–74 7,655 Died 2,000
986 Division of abdominal adhesions 1,387 75–84 6,421 Other 21,059
1963 Computerised tomography of abdomen and pelvis 1,339 85+ 1,905 Not reported 1
  Note:   Main abbreviations:  ALOS—average length of stay, W—with, W/O—without, Cat—catastrophic, CC—complication or comorbidity. ALOS excludes same-day patients.
Figure 20: Inpatients with a principal diagnosis of colorectal cancer, all hospitals, Australia, 2000–2001
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Lung cancer—ICD-10-AM C33 & C34
Figure 21 presents the interrelationships with various data elements where the principal
diagnosis was lung cancer. Lung cancer includes Malignant neoplasm of trachea (C33) and
Malignant neoplasm of bronchus and lung (C34).
There were 17,085 separations where lung cancer was recorded as the principal diagnosis. Of
these, 3,475 (20%) were same-day patients. For non-same-day patients, the average length of
stay was 9.5 days. Other key points from the figure are:
• 73% of separations were in the public sector.
• 64% of separations were for public patients.
• 66% of separations were for males.
• The 65–74 years age group had the largest number of separations (37%).
• The majority of patients (84%) had acute care and 16% had palliative care.
• A large proportion of patients (70%) had a separation mode of Other, indicating that
these patients went home after separation from hospital, whereas 19% had a separation
mode of Died.
• The most common diagnosis in addition to a principal diagnosis of lung cancer was
Personal history of tobacco use disorder (Z86.43).
• The most common surgical procedure performed was Bronchoscopy with biopsy or removal
of foreign body (Block 544).
• The most commonly reported AR-DRG was Respiratory neoplasms with complication or
comorbidity (AR-DRG E71A).
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Additional diagnoses (top 10)  State or Territory AR-DRGs (top 10)
Z86.43 Personal history of tobacco use disorder 4,290 NSW 4,125 E71A Respiratory Neoplasms W CC 9,350
Z51.5 Palliative care 3,150 VIC 3,204 E71B Respiratory Neoplasms W/O CC 2,757
Z72.0 Tobacco use, current 2,669 QLD 2,426 E02C Other Respiratory System OR Procedures W/O 1,929
C79.5 Secondary malignant neoplasm of  bone and bone marrow 2,376 WA 862 Catastrophic or Severe CC
Z51.1 Chemotherapy session for neoplasm 1,798 SA 1,346 E01B Major Chest Procedure W/O Catastrophic CC 1,138
C78.7 Secondary malignant neoplasm of  liver 1,771 TAS 303 E02A Other Respiratory System OR Procedures W Cat CC 656
C77.1 Secondary and unspecif ied malignant neoplasm of 1,710 ACT 158 E02B Other Respiratory System OR Procedures W Severe CC 595
intrathoracic lymph nodes NT 55 E01A Major Chest Procedure W Catastrophic CC 530
J44.9 Chronic obstructive pulmonary disease, unspecif ied 1,604 A06Z Tracheostomy Any Age Any Condition 46
C79.3 Secondary malignant neoplasm of  brain and cerebral meninges 1,548 901Z Extensive OR Procedure Unrelated to Principal Diagnosis 36
I10 Essential (primary) hypertension 1,454 B60B Non Acute Paraplegia/Quadriplegia W or W/O OR 14
Procedures W/O Catastrophic CC
Medicare eligibility and funding source Care type
Medicare eligible 16,977 PRINCIPAL DIAGNOSIS Acute 14,272
Public 10,868 Sector C33 & C34 Lung cancer Rehab 3
Private 6,109 Public 12,479 Separations 17,085 Palliative 2,666
    Compensable 34 Private 4,606 Patient days 132,225 Geriatric evaluation 34
    Dept of  Veterans' Af fairs 1,911 ALOS (days) 9.5  Sex Psychogeriatric 1
    Other private 4,164  Male 11,239 Maintenance 39
Not Medicare eligible 32  Female 5,846 New born 0
Not reported 76 Other care 10
Not reported 60
Procedure block (top 10)
1916 Generalised allied health interventions 6,399  Age group Separation m ode
544 Bronchoscopy w ith biopsy or removal of foreign body 3,010 0–4 4 Discharge/transfer to an(other)acute hospital 1,132
1910 General anaesthesia 2,464 5–14 7 Discharge/transfer to a residential aged care service 176
1911 Sedation 2,313 15–24 14 Discharge/transfer to an(other) psychiatric hospital 1
1780 Chemotherapy administration 2,209 25–34 51 Discharge/transfer to other health care accommodation 92
1960 Computerised tomography of  chest 1,615 35–44 451 Statistical discharge—type change 394
1893 Transfusion of blood and gamma globulin 1,586 45–54 1,580 Lef t against medical advice 35
550 Biopsy of  lung or pleura 1,203 55–64 3,865 Statistical discharge from leave 34
1952 Computerised tomography of  brain 1,044 65–74 6,258 Died 3,283
560 Application, insertion or removal procedures on chest w all, 945 75–84 4,233 Other 11,936
mediastinum or diaphragm 85+ 622 Not reported 2
  Note:   Main abbreviations:  ALOS—average length of  stay, W—w ith, W/O—w ithout, Cat—catastrophic, CC—complication or comorbidity, OR—operating room. ALOS excludes same-day patients.
Figure 21: Inpatients with a principal diagnosis of lung cancer, all hospitals, Australia, 2000–2001
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Melanoma skin cancer—ICD-10-AM C43
Figure 22 presents the interrelationships with various data elements where the principal
diagnosis was melanoma. Melanoma skin cancer includes Malignant melanoma of skin (C43).
There were 7,698 separations where melanoma was recorded as the principal diagnosis. Of
these, 4,935 (64%) were same-day patients. For non-same-day patients, the average length of
stay was 5.7 days. Other key points from the figure are:
• 46% of separations were in the public sector.
• 39% of separations were for public patients.
• 56% of separations were for males.
• The 65–74 years age group had the largest number of separations (21%).
• The majority of patients (96%) had acute care and 3% had palliative care.
• A large proportion of patients (95%) had a separation mode of Other, indicating that
these patients went home after separation from hospital, whereas 3% had a separation
mode of Died.
• The most common diagnosis in addition to a principal diagnosis of melanoma was
Essential (primary) hypertension (I10).
• The most common surgical procedures performed were excisions (Blocks 1624 and 1623).
• The most commonly reported AR-DRG was Other Skin, Subcutaneous Tissue and Breast
Procedures (AR-DRG J11Z).
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Additional diagnoses (top 10) State  or Territory AR-DRGs (top 10)
I10 Essential (primary) hypertension 485 NSW 1,203 J11Z Other Skin, Subcutaneous Tissue and Breast Procedures 4,188
Z72.0 Tobacco use, current 423 VIC 772 J08B Other Skin Graft and/or Debridement Procedures 1,247
Z86.43 Personal history of  tobacco use disorder 335 QLD 872 W/O Catastrophic or Severe CC
D22.5 Melanocytic naevi of  trunk 274 WA 216 J03B Low er Limb W Skin Graft/Flap Repair W/O Ulcer/Cellulitis 738
E11.9 Type 2 diabetes mellitus w ithout complication 258 SA 324 W/O Catastrophic or Severe CC
C78.0 Secondary malignant neoplasm of  lung 250 TAS 85 J66B Moderate Skin Disorders W/O Catastrophic or Severe CC 480
Z51.5 Palliative care 225 ACT 19 J66A Moderate Skin Disorders W Catastrophic or Severe CC 399
L57/0 Actinic keratosis 223 NT 20 J10Z Skin, Subcutaneous Tissue and Breast Plastic OR Procedures 235
L82 Seborrhoeic keratosis 198 J05Z Low er Limb W Other OR Proc W/O Skin Graf t/Flap 158
C79.3 Secondary malignant neoplasm of  brain and 155 Repair W/O Ulcer/Cellulitis
cerebral meninges J08A Other Skin Graft and/or Debridement Procedures W Catastrophic 83
or Severe CC
J03A Low er Limb W Skin Graft/Flap Repair W/O Ulcer/Cellulitis 68
W Catastrophic or Severe CC
Medicare eligibility and funding source C11Z Eyelid Procedures 34
Medicare eligible 7,619
Public 2,964 Care type
Private 4,655 PRINCIPAL DIAGNOSIS Acute 7,425
    Compensable 70 Sector C43 Melanoma Rehab 0
    Dept of  Veterans' Af fairs 677 Public 3,511 Separations 7,698 Palliative 210
    Other private 3,908 Private 4,187 Patient days 20,607 Geriatric evaluation 0
Not Medicare eligible 6 ALOS (days) 5.7  Sex Psychogeriatric 22
Not reported 73  Male 4,314 Maintenance 3
 Female 3,384 New born 0
Other care 4
Procedure block (top 10) Not reported 34
1624 Excision of  residual or recurrent basal cell or squamous 3,351
cell carcinoma of skin  Age group Separation m ode
1623 Excision of  other malignant lesion of  skin and 3,163 0–4 1 Discharge/transfer to an(other)acute hospital 50
subcutaneous tissue 5–14 18 Discharge/transfer to a residential aged care service 35
1910 General anaesthesia 3,090 15–24 163 Discharge/transfer to an(other) psychiatric hospital 0
1911 Sedation 1,479 25–34 468 Discharge/transfer to other health care accommodation 20
1645 Other split skin graf t, small 690 35–44 919 Statistical discharge—type change 47
1651 Local skin f lap, simple and small, single stage 681 45–54 1,367 Left against medical advice 7
1620 Excision of  benign lesion of  skin and subcutaneous tissue 669 55–64 1,432 Statistical discharge from leave 5
1916 Generalised allied health interventions 513 65–74 1,616 Died 211
1622 Excision of  basal cell or squamous cell carcinoma of  skin 437 75–84 1,364 Other 7,323
805 Biopsy of  lymphatic structure 348 85+ 350 Not reported 0
  Note:   Main abbreviations:  ALOS—average length of  stay, W—w ith, W/O—w ithout, Cat—catastrophic, CC—complication or comorbidity, OR—operating room. ALOS excludes same-day patients.
Figure 22: Inpatients with a principal diagnosis of melanoma, all hospitals, Australia, 2000–2001
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Non-melanocytic skin cancer—ICD-10-AM C44
Figure 23 presents the interrelationships with various data elements where the principal
diagnosis was non-melanocytic skin cancer (NMSC). NMSC includes Other malignant
neoplasms of skin (C44).
There were 65,616 separations where non-melanocytic skin cancer was recorded as the
principal diagnosis. Of these, 51,395 (78%) were same-day patients. For non-same-day
patients, the average length of stay was 4.2 days. Other key points from the figure are:
• 37% of separations were in the public sector.
• 32% of separations were for public patients.
• 61% of separations were for males.
• The 75–84 years age group had the largest number of separations (34%).
• The majority of patients (99%) had acute care and less than 1% had palliative care.
• A large proportion of patients (98%) had a separation mode of Other, indicating that
these patients went home after separation from hospital, whereas less than 1% had a
separation mode of Died.
• The most common diagnosis in addition to a principal diagnosis of NMSC was Actinic
keratosis (L57.0).
• The most common procedure performed was Excision of basal cell or squamous cell
carcinoma of skin (Block 1622).
• The most commonly reported AR-DRG was Other Skin, Subcutaneous Tissue and Breast
Procedures (AR-DRG J11Z).
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Additional diagnoses  (top 10) State  or Territory AR-DRGs (top 10)
L57.0 Actinic keratosis 8,853 NSW 6,204 J11Z Other Skin, Subcutaneous Tissue and Breast Procedures 22,719
C44.3 Malignant neoplasm of  skin of  other and 3,476 VIC 4,856 J08B Other Skin Graf t and/or Debridement Procedures W/O 15,162
unspecif ied parts of  face QLD 6,474 Catastrophic or Severe CC
I10 Essential (primary) hypertension 3,353 WA 2,147 J10Z Skin, Subcutaneous Tissue and Breast Plastic OR Procedures 11,975
Z72.0 Tobacco use, current 2,940 SA 3,472 J67B Minor Skin Disorders W/O CC 3,828
Z86.43 Personal history of  tobacco use disorder 2,737 TAS 431 J03B Low er Limb W Skin Graf t/Flap Repair W/O Ulcer/Cellulitis 3,677
C44.6 Malignant neoplasm of  skin of  upper limb, including shoulder 2,685 ACT 326 W/O Cat or Severe CC
L82 Seborrhoeic keratosis 2,542 NT 109 C11Z Eyelid Procedures 3,274
E11.9 Type 2 diabetes mellitus w ithout complication 2,090 C14Z Other Eye Procedures 1,924
C44.5 Malignant neoplasm of  skin of  trunk 1,995 J08A Other Skin Graf t and/or Debridement Procedures W 693
C44.4 Malignant neoplasm of  skin of  scalp and neck 1,880 Catastrophic or Severe CC
J67A Minor Skin Disorders W CC 435
J66B Moderate Skin Disorders W/O Catastrophic or Severe CC 415
Medicare  eligibility and funding source
Medicare eligible 64,709 Care  type
Public 21,249 Sector PRINCIPAL DIAGNOSIS Acute 64,992
Private 43,460 Public 24,019 C44 Non-melanocytic skin cancer Rehab 0
    Compensable 590 Private 41,597 Separations 65,616 Palliative 97
    Dept of  Veterans' Af fairs 10,111 Patient days 111,434  Sex Geriatric evaluation 2
    Other private 32,759 ALOS (days) 4.2  Male 39,054 Psychogeriatric 51
Not Medicare eligible 76  Female 26,561 Maintenance 28
Not reported 831 New born 0
Other care 17
Not reported 429
Procedure  block  (top 10)
1622 Excision of  basal cell or squamous cell carcinoma of  skin 52,030  Age  group Separation m ode
1911 Sedation 16,914 0–4 10 Discharge/transfer to an(other)acute hospital 243
1910 General anaesthesia 14,696 5–14 27 Discharge/transfer to a residential aged care service 324
1651 Local skin f lap, simple and small, single stage 14,524 15–24 142 Discharge/transfer to an(other) psychiatric hospital 5
1649 Other full thickness skin graf t 10,864 25–34 1,017 Discharge/transfer to other health care accommodation 112
1625 Excision of  lesion of  skin and subcutaneous tissue, NEC 7,198 35–44 3,602 Statistical discharge—type change 380
1620 Excision of  benign lesion of  skin and subcutaneous tissue 6,953 45–54 8,289 Lef t against medical advice 42
1624 Excision of  residual or recurrent basal cell or squamous 6,808 55–64 11,167 Statistical discharge f rom leave 10
cell carcinoma of  skin 65–74 15,531 Died 123
1645 Other split skin graf t, small 5,890 75–84 18,953 Other 64,377
1652 Local skin f lap, large or complicated, single stage 2,710 85+ 6,878 Not reported 0
  Note:  Main abbreviations: ALOS—average length of  stay, W—w ith, W/O—w ithout, Cat—catastrophic, CC—complication or comorbidity, OR—operating room, NEC—not elsew here classif ied.
   ALOS excludes same-day patients. One person w as of  unknow n sex.
Figure 23: Inpatients with a principal diagnosis of non-melanocytic skin cancer, all hospitals, Australia, 2000–2001
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Breast cancer—ICD-10-AM C50
Figure 24 presents the interrelationships with various data elements where the principal
diagnosis was breast cancer. Breast cancer includes Malignant neoplasm of breast (C50). The
analysis of breast cancer was restricted to females only.
There were 20,382 separations where breast cancer was recorded as the principal diagnosis.
Of these, 4,804 (24%) were same-day patients. For non-same-day patients, the average length
of stay was 5.2 days. Other key points from the figure are:
• 50% of separations were in the public sector.
• 46% of separations were for public patients.
• The 45–54 years age group had the largest number of separations (27%).
• The majority of patients (95%) had acute care and 4% had palliative care.
• A large proportion of patients (93%) had a separation mode of Other, indicating that
these patients went home after separation from hospital, whereas 3% had a separation
mode of Died.
• The most common diagnosis in addition to a principal diagnosis of breast cancer was
Secondary and unspecified malignant neoplasm of axillary and upper limb lymph nodes (C77.3).
• The most common surgical procedure performed was Local excision of breast (Block 1744).
• The most commonly reported AR-DRG was Major Procedures for Malignant Breast
Conditions (AR-DRG J06A).
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Additional diagnoses (top 10)  State  or Territory AR-DRGs (top 10)
C77.3 Secondary and unspecif ied malignant neoplasm of  axillary 4,767 NSW 3,180 J06A Major Procedures for Malignant Breast Conditions 10,647
and upper limb lymph nodes VIC 3,162 J07A Minor Procedures for Malignant Breast Conditions 3,452
C79.5 Secondary malignant neoplasm of  bone and bone marrow 2,165 QLD 1,566 J62B Mal Breast Disorders (Age<70 W CC) or (Age>69 W/O CC) 3,102
Z72.0 Tobacco use, current 1,475 WA 848 J62C Malignant Breast Disorders Age<70 W/O CC 1,530
I10 Essential (primary) hypertension 1,308 SA 1,068 J62A Malignant Breast Disorders Age>69 W CC 1,155
Z51.1 Chemotherapy session for neoplasm 1,275 TAS 188 J11Z Other Skin, Subcutaneous Tissue and Breast Procedures 371
D05.1 Intraductal carcinoma in situ of  breast 1,072 ACT 184 J01Z Microvascular Tissue Transfer for Skin, Subcutaneous 52
Z86.43 Personal history of  tobacco use disorder 1,015 NT 37 Tissue & Breast Disorder
Z51.5 Palliative care 844 901Z Extensive OR Procedure Unrelated to Principal Diagnosis 21
E11.9 Type 2 diabetes mellitus w ithout complication 837 B60B Non Acute Paraplegia/Quadriplegia W or W/O OR 11
C78.7 Secondary malignant neoplasm of  liver 820 Procedures W/O Cat CC
J08A Other Skin Graf t and/or Debridement Procedures 10
W Cat or Severe CC
M edicare  e ligibility and funding source
Medicare eligible 20,100 Care type
Public 9,370 Sector PRINCIPAL DIAGNOSIS Acute 19,335
Private 10,730 Public 10,233 C50 Breast cancer Rehab 3
    Compensable 45 Private 10,149 Separations 20,382 Palliative 768
    Dept of  Veterans' Af fairs 400 Patient days 85,347 Geriatric evaluation 18
    Other private 10,285 ALOS (days) 5.2 Psychogeriatric 38
Not Medicare eligible 32 Maintenance 7
Not reported 250 New born 0
Other care 70
Not reported 143
Procedure block (top 10)  Age group Separation m ode
1910 General anaesthesia 14,112 0–4 0 Discharge/transfer to an(other)acute hospital 273
1744 Local excision of  breast 6,758 5–14 0 Discharge/transfer to a residential aged care service 79
808 Excision procedures on lymph node of  axilla 6,637 15–24 26 Discharge/transfer to an(other) psychiatric hospital 0
1916 Generalised allied health interventions 5,686 25–34 435 Discharge/transfer to other health care accommodation 37
1750 Modif ied radical mastectomy 2,411 35–44 2,570 Statistical discharge—type change 290
1740 Examination procedures on breast 2,031 45–54 5,590 Left against medical advice 11
1885 Injection or infusion of  theraputic or prophlyactic substance 1,701 55–64 5,108 Statistical discharge f rom leave 18
1780 Chemotherapy administration 1,486 65–74 3,803 Died 669
1746 Partial mastectomy 1,481 75–84 2,277 Other 19,003
1748 Simple mastectomy 1,317 85+ 573 Not reported 2
  Note:   Main abbreviations:  ALOS—average length of  stay (excludes same-day), W—w ith, W/O—w ithout, Cat—catastrophic, CC—complication or comorbidity, Mal—malignant, OR—operating room.
Figure 24: Inpatients with a principal diagnosis of breast cancer, all hospitals, Australia, 2000–2001
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Cancer of the cervix—ICD-10-AM C53
Figure 25 presents the interrelationships with various data elements where the principal
diagnosis was cancer of the cervix. Cervical cancer includes Malignant neoplasm of cervix uteri
(C53).
There were 1,920 separations where cervical cancer was recorded as the principal diagnosis.
Of these, 516 (27%) were same-day patients. For non-same-day patients, the average length
of stay was 7.6 days. Other key points from the figure are:
• 76% of separations were in the public sector.
• 67% of separations were for public patients.
• The 45–54 years age group had the largest number of separations (23%).
• The majority of patients (94%) had acute care and 5% had palliative care.
• A large proportion of patients (88%) had a separation mode of Other, indicating that
these patients went home after separation from hospital, whereas 5% had a separation
mode of Died.
• The most common diagnosis in addition to a principal diagnosis of cancer of the cervix
was Tobacco use, current (Z72.0).
• The most common surgical procedure performed was Excision procedures on cervix (Block
1276).
• The most commonly reported AR-DRG was Conisation, Vagina, Cervix and Vulva
Procedures (AR-DRG N09Z).
59
Additional diagnoses (top 10)  State  or Territory AR-DRGs (top 10)
Z72.0 Tobacco use, current 258 NSW 479 N09Z Conisation, Vagina, Cervix and Vulva Procedures 741
Z51.0 Radiotherapy session 196 VIC 382 N60B Mal, Female Reproductive System W/O Cat or Severe CC 442
Z51.1 Chemotherapy session for neoplasm 176 QLD 304 N60A Mal, Female Reproductive System W Cat or Severe CC 273
C77.5 Secondary and unspecif ied malignant neoplasm of 167 WA 118 N03B Uterine, Adnexa Proc for Non-Ovarian or Adnexal Mal W/O CC 183
intrapelvic lymph nodes SA 151 N03A Uterine, Adnexa Proc for Non-Ovarian or Adnexal Mal W CC 164
I10 Essential (primary) hypertension 147 TAS 10 N10Z Diagnostic Curettage or Diagnostic Hysteroscopy 39
Z51.5 Palliative care 128 ACT 14 N01Z Pelvic Evisceration and Radical Vulvectomy 27
Z86.43 Personal history of  tobacco use disorder 120 NT 2 N11A Other Female Reproductive Sys OR Procs Age>64 25
D63.0 Anaemia in neoplastic disease 116 or W Malignancy or W CC
E11.9 Type 2 diabetes mellitus w ithout complication 110 N08Z Endoscopic Procedures for Female Reproductive System 14
N39.0 Urinary tract infection, site not specif ied 90 901Z Extensive OR Procedure Unrelated to Principal Diagnosis 8
Care  type
Medicare  e ligibility and funding source Acute 1,809
Medicare eligible 1,881 PRINCIPAL DIAGNOSIS Rehab 0
Public 1,282 Sector C53 Cervical cancer Palliative 103
Private 599 Public 1,460 Separations 1,920 Geriatric evaluation 1
    Compensable 3 Private 460 Patient days 11,236 Psychogeriatric 3
    Dept of  Veterans' Af fairs 53 ALOS (days) 7.6 Maintenance 0
    Other private 543 New born 0
Not Medicare eligible 36 Other care 0
Not reported 3 Not reported 4
Procedure  block (top 10)  Age group Separation m ode
1910 General anaesthesia 1,130 0–4 0 Discharge/transfer to an(other)acute hospital 100
1916 Generalised allied health interventions 549 5–14 0 Discharge/transfer to a residential aged care service 15
1276 Excision procedures on cervix 415 15–24 10 Discharge/transfer to an(other) psychiatric hospital 2
1088 Examination procedures on bladder 293 25–34 191 Discharge/transfer to other health care accommodation 7
1268 Abdominal hysterectomy 263 35–44 334 Statistical discharge—type change 10
1893 Transfusion of  blood and gamma globulin 236 45–54 442 Lef t against medical advice 4
1790 Brachytherapy, intracavitary, gynaecological 222 55–64 332 Statistical discharge f rom leave 1
1780 Chemotherapy administration 202 65–74 300 Died 92
1265 Curettage of  uterus 182 75–84 246 Other 1,689
1788 Megavoltage radiation treatment 109 85+ 65 Not reported 0
  Note:   Main abbreviations:  ALOS—average length of  stay, W—w ith, W/O—w ithout, Cat—catastrophic, CC—complication or comorbidity, Proc—procedure, Mal—malignancy,
  OR—operating room. ALOS excludes same-day patients.
Figure 25: Inpatients with a principal diagnosis of cervical cancer, all hospitals, Australia, 2000–2001
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Prostate cancer—ICD-10-AM C61
Figure 26 presents the interrelationships with various data elements where the principal
diagnosis was prostate cancer. Prostate cancer includes Malignant neoplasm of prostate (C61).
There were 13,693 separations where prostate cancer was recorded as the principal
diagnosis. Of these, 3,203 (23%) were same-day patients. For non-same-day patients, the
average length of stay was 7.4 days. Other key points from the figure are:
• 43% of separations were in the public sector.
• 34% of separations were for public patients.
• The 75–84 years age group had the largest number of separations (34%).
• The majority of patients (91%) had acute care and 7% had palliative care.
• A large proportion of patients (87%) had a separation mode of Other, indicating that
these patients went home after separation from hospital, whereas 7% had a separation
mode of Died.
• The most common diagnosis in addition to a principal diagnosis of prostate cancer was
Secondary malignant neoplasm of bone and bone marrow (C79.5).
• The most common surgical procedure performed was Transurethral prostatectomy
(Block 1165).
• The most commonly reported AR-DRG was Malignancy, Male Reproductive System Without
Catastrophic or Severe Complication or Comorbidity (AR-DRG M60B).
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Additional diagnoses (top 10)  State or Territory AR-DRGs (top 10)
C79.5 Secondary malignant neoplasm of  bone and bone marrow 2,522 NSW 2,050 M60B Mal, Male Reproductive System W/O Cat or Severe CC 3,675
Z86.43 Personal history of  tobacco use disorder 1,451 VIC 1,546 M02B Transurethral Prostatectomy W/O Cat or Severe CC 3,267
I10 Essential (primary) hypertension 1,255 QLD 991 M60A Mal, Male Reproductive System W Cat or Severe CC 2,186
Z51.5 Palliative care 1,018 WA 318 M01Z Major Male Pelvic Procedures 1,999
E11.9 Type 2 diabetes mellitus w ithout complication 1,001 SA 660 M02A Transurethral Prostatectomy W Cat or Severe CC 831
D63.0 Anaemia in neoplastic disease 993 TAS 183 M06A Other Male Reproductive System OR Procedures for Mal 587
N40 Hyperplasia of  prostate 835 ACT 94 M40Z Cystourethroscopy W/O CC 563
R33 Retention of urine 833 NT 8 M04B Testes Procedures W/O CC 342
Z72.0 Tobacco use, current 721 M04A Testes Procedures W CC 110
N32.8 Other specif ied disorders of  bladder 593 901Z Extensive OR Procedure Unrelated to Principal Diagnosis 45
Medicare eligibility and funding source
Medicare eligible 13,477 PRINCIPAL DIAGNOSIS Care type
Public 4,637 Sector C61 Prostate cancer Acute 12,460
Private 8,840 Public 5,850 Separations 13,693 Rehab 3
    Compensable 36 Private 7,843 Patient days 80,418 Palliative 983
    Dept of  Veterans' Af fairs 2,434 ALOS (days) 7.4 Geriatric evaluation 19
    Other private 6,370 Psychogeriatric 22
Not Medicare eligible 43 Maintenance 36
Not reported 173 New born 0
Other care 13
Not reported 157
Procedure block (top 10)  Age group Separation mode
1910 General anaesthesia 5,206 0–4 0 Discharge/transfer to an(other)acute hospital 348
1165 Transurethral prostatectomy 3,994 5–14 0 Discharge/transfer to a residential aged care service 152
1916 Generalised allied health interventions 2,969 15–24 0 Discharge/transfer to an(other) psychiatric hospital 3
1893 Transfusion of blood and gamma globulin 2,358 25–34 1 Discharge/transfer to other health care accommodation 30
1163 Closed biopsy of prostate or seminal vesicle 2,233 35–44 30 Statistical discharge—type change 241
1167 Open prostatectomy 2,005 45–54 578 Left against medical advice 9
36 Spinal injection 1,745 55–64 2,664 Statistical discharge f rom leave 14
1943 Ultrasound of abdomen or pelvis 1,571 65–74 4,504 Died 922
1088 Examination procedures on bladder 996 75–84 4,644 Other 11,974
1089 Urinary catheterisation 671 85+ 1,272 Not reported 0
  Note:  Main abbreviations: ALOS—average length of stay (excludes same-day), W—w ith, W/O—w ithout, Cat—catastrophic, CC—complication or comorbidity, Mal—malignancy, OR—operating room.
Figure 26: Inpatients with a principal diagnosis of prostate cancer, all hospitals, Australia, 2000–2001
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Non-Hodgkin’s lymphoma—ICD-10-AM C82–C85 & C96
Figure 27 presents the interrelationships with various data elements where the principal
diagnosis is non-Hodgkin’s lymphoma. Non-Hodgkin’s lymphoma includes Follicular
(nodular) non-Hodgkin’s lymphoma (C82), Diffuse non-Hodgkin’s lymphoma (C83), Peripheral and
cutaneous T-cell lymphomas (C84), Other and unspecified types of non-Hodgkin’s lymphoma (C85)
and Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue
(C96).
There were 16,061 separations where non-Hodgkin’s lymphoma was recorded as the
principal diagnosis. Of these, 6,507 (41%) were same-day patients. For non-same-day
patients, the average length of stay was 8.3 days. Other key points from the figure are:
• 62% of separations were in the public sector.
• 52% of separations were for public patients.
• 56% of separations were for males.
• The 65–74 years age group had the largest number of separations (24%).
• The majority of patients (96%) had acute care and 3% had palliative care.
• A large proportion of patients (88%) had a separation mode of Other, indicating that
these patients went home after separation from hospital, whereas 6% had a separation
mode of Died.
• The most common diagnosis in addition to a principal diagnosis of non-Hodgkin’s
lymphoma was Chemotherapy session for neoplasm (Z51.1).
• The most common procedures performed were Chemotherapy administration (Block 1780),
Transfusion of blood and gamma globulin (Block 1893) and Biopsy of bone marrow (Block 800).
• The most commonly reported AR-DRG was Lymphoma and Non-Acute Leukaemia without
Catastrophic Complication or Comorbidity (AR-DRG R61B).
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Additional diagnoses (top 10)  State  or Terr itory AR-DRGs (top 10)
Z51.1 Chemotherapy session for neoplasm 3,735 NSW 2,738 R61B Lymphoma and Non-Acute Leukaemia W/O Cat CC 6,237
D63.0 Anaemia in neoplastic disease 1,858 VIC 2,898 R61C Lymphoma and Non-Acute Leukaemia, Sameday 5,659
Z86.43 Personal history of  tobacco use disorder 1,027 QLD 2,126 R03B Lymphoma and Leukaemia W Other OR Procedures 1,559
I10 Essential (primary) hypertension 852 WA 814 W/O Catastrophic or Severe CC
E11.9 Type 2 diabetes mellitus w ithout complication 814 SA 958 R61A Lymphoma and Non-Acute Leukaemia W Cat CC 957
Z51.5 Palliative care 714 TAS 167 R01B Lymphoma and Leukaemia W Major OR Procedures 541
Z72.0 Tobacco use, current 627 ACT 216 W/O Catastrophic or Severe CC
D70 Agranulocytosis 587 NT 29 R03A Lymphoma and Leukaemia W Other OR Procedures 386
R50.9 Fever, unspecif ied 540 W Catastrophic or Severe CC
Z95.8 Presence of  other cardiac and vascular implants and graf ts 451 R01A Lymphoma and Leukaemia W Major OR Procedures 318
W Catastrophic or Severe CC
A04Z Bone Marrow  Transplant 263
S62Z HIV-Related Malignancy 69
A06Z Tracheostomy Any Age Any Condition 27
M edicare  e ligibility and funding source
Medicare eligible 15,931 Care  type
Public 8,292 Sector PRINCIPAL DIAGNOSIS Acute 15,397
Private 7,639 Public 9,946 C82, C83, C84, C85 & C96 Rehab 3
    Compensable 33 Private 6,115 Non-Hodgkin's Lymphoma Palliative 526
    Dept of  Veterans' Af fairs 1,182 Separations 16,061  Sex Geriatric evaluation 17
    Other private 6,424 Patient days 85,348  Male 8,916 Psychogeriatric 7
Not Medicare eligible 50 ALOS (days) 8.3  Female 7,145 Maintenance 7
Not reported 80 New born 0
Other care 10
Not reported 94
Procedure block (top 10)  Age group Separation m ode
1780 Chemotherapy administration 4,476 0–4 80 Discharge/transfer to an(other)acute hospital 595
1893 Transfusion of  blood and gamma globulin 4,262 5–14 386 Discharge/transfer to a residential aged care service 78
1916 Generalised allied health interventions 3,230 15–24 270 Discharge/transfer to an(other) psychiatric hospital 1
800 Biopsy of  bone marrow 2,815 25–34 500 Discharge/transfer to other health care accommodation 48
1910 General anaesthesia 2,492 35–44 1,186 Statistical discharge—type change 179
1885 Injection or infusion of  therapeutic or prophylactic substance 1,819 45–54 2,530 Left against medical advice 21
1911 Sedation 1,460 55–64 3,575 Statistical discharge f rom leave 15
738 Venous catheterisation 802 65–74 3,862 Died 916
1961 Computerised tomography of  chest, abdomen and pelvis 752 75–84 2,993 Other 14,206
805 Biopsy of  lymphatic structure 739 85+ 679 Not reported 2
  Note:   Main abbreviations:  ALOS—average length of  stay, W—w ith, W/O—w ithout, Cat—catastrophic, CC—complication or comorbidity, OR—operating room. ALOS excludes same-day patients.
Figure 27: Inpatients with a principal diagnosis of non-Hodgkin’s lymphoma, all hospitals, Australia, 2000–2001
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All priority cancers
Each of the eight priority cancers analysed included the following in their top ten additional
diagnoses:
• I10—Essential (primary) hypertension
• Z72.0—Tobacco use, current
• Z86.43—Personal history of tobacco use disorder
All priority cancers with the exception of lung cancer included E11.9—Type 2 diabetes
mellitus without complication amongst the top ten additional diagnoses, and all with the
exception of non-melanocytic skin cancer included Z51.5—Palliative care.
Each of the priority cancers analysed included 1910—General anaesthesia amongst the top
ten procedures. All priority cancers with the exception of non-melanocytic skin cancer
included 1916—Generalised allied health interventions amongst the top ten procedures.
Non-melanocytic skin cancer was the principal diagnosis associated with the greatest
number of separations. This cancer had the largest proportion of same-day patients.
Colorectal cancer was the principal diagnosis associated with the longest average length of
stay for non-same-day patients.
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Cancer workforce
The Australian Institute of Health and Welfare publishes health workforce statistics from
three main sources:
• national collections in conjunction with State and Territory health authorities for the
registered health occupations;
• Medicare provider statistics tabulated by the Commonwealth Department of Health and
Ageing; and
• the 5-yearly population census conducted by the Australian Bureau of Statistics.
Health workforce statistics are also collected in surveys and censuses by professional bodies,
and in a number of other private regular and ad hoc data collections.
The cancer workforce comprises:
• a diagnostic workforce, including members of the workforce for the national screening
programs;
• a medical treatment workforce of medical and nursing professionals;
• a palliative and hospice care workforce;
• a paid and voluntary patient support workforce including counsellors and cancer
support organisations; and
• a public health workforce including cancer registries, the State and Territory cancer
councils, other health promotion groups, Commonwealth, State and local government
cancer control units, and research bodies.
Data on these are limited, incomplete and generally not up to date. They include the
following.
Medical workforce
Almost all medical practitioners in Australia treat some persons with cancer. Several medical
specialties have a high proportion of patients with cancer. The 1995 and 1998 national figures
for these are seen in Table 10.
In its 2001 review of the specialist medical and haematological oncology workforce in
Australia, the Australian Medical Workforce Advisory Committee (AMWAC) reported that
there were 337 medical and haematological oncologists in 2000, and there was both a
shortage of these oncologists and a maldistribution of the existing workforce (AMWAC
2001a).
In its 2001 review of the specialist radiology workforce, AMWAC reported that there were
1,148 specialist radiologists in 2000, and that this workforce was also undersupplied
(AMWAC 2001b).
AMWAC also reviewed the specialist radiation oncology workforce in 1998 and found
shortages in that workforce (AMWAC 1998). In each case AMWAC recommended increases
in training numbers to address the shortage and ongoing annual growth in demand for
cancer services.
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Table 10: Medical specialties with a high proportion of patients with cancer, 1995 and 1998
Medical specialty 1995 1998
Number of practising specialists
Medical oncology 154 167
Radiation oncology 127 152
Clinical haematology 133 135
Haematology 66 61
Nuclear medicine 129 141
Total 609 656
Source: AIHW: Medical Labour Force 1995, Medical Labour Force 1998.
Nursing workforce
In 1997, there were 2,412 registered nurses and 273 enrolled nurses working in oncology as
their main field of nursing practice. There were also 813 registered nurses and 244 enrolled
nurses employed in hospices (AIHW: Nursing Labour Force 1999).
Medical imaging workforce
At the 1996 census there were 4,719 medical diagnostic radiographers, 701 radiation
therapists, 400 nuclear medicine technologists and 704 sonographers employed in Australia
(Australian Bureau of Statistics).
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General practice and cancer patients
The continuous national study of general practice activity in Australia, known as the BEACH
(Bettering the Evaluation and Care of Health) program, provides insight into the patients
and problems managed in general practice and the ways in which GPs manage the problems.
In BEACH, a random sample of about 1,000 GPs provides details of around 100,000
GP–patient encounters each year. The study is conducted by the General Practice Statistics
and Classification Unit (GPSCU—an AIHW collaborating unit within the Family Medicine
Research Centre, University of Sydney).  The data tables in this section have been prepared
by the GPSCU and there are further detailed GPSCU analyses of BEACH data in reports on
both the AIHW web site and the GPSCU web site www.fmrc.org.au/beach.htm.
This section represents a summary of the data collected in the first four years of the study,
between April 1998 and March 2002. It provides information about those problems that the
GP labelled as any type of cancer. These data are drawn from 4,013 GPs and represent a
database of 401,300 encounters. The participating GPs were randomly selected from the
Health Insurance Commission list of active GPs (those who provided more than 375 GP
services in the previous quarter). Each GP completed a paper encounter record for each of
100 encounters. Data elements included:
• date of encounter
• service item number/form of payment/indirect encounters (for example, telephone
consultations)
• patient age and sex and other socio-demographics
• patient’s reasons for encounter (up to three)
• diagnoses/problems managed (up to four)
• status of each problem to the patient (new/old)
• medications prescribed (up to four per problem)
• other treatments provided (up to two per problem)
• referral, pathology tests and imaging ordered.
Cancers were managed at a rate of 18.8 per 1,000 GP–patient encounters. Extrapolated to the
total GP–patient encounters in any one year across the country, these data suggest there are
about two million encounters in general practice in which a cancer is managed. Table 11
presents the top ten types of cancer reported by GPs in these encounters. These ten types of
cancer together accounted for around 78% of the GP–patient contacts with a cancer. The top
three types—basal and squamous cell carcinoma and prostate cancer—accounted for around
51% of cancers managed. All skin cancers (both melanoma and non-melanocytic skin
cancers) together accounted for around 46% of cancers managed at these encounters.
Table 12 summarises details of the GPs’ management of cancer. GPs prescribed, advised or
supplied medications at a rate of 31 medications per 100 problems. The majority of these
were prescribed (29.0 per 100 cancer contacts), with the remainder being medication
supplied by the GP (1.4 per 100) or over-the-counter medication advised by the GP (0.6 per
100).
GPs provided other treatments at a rate of 40.0 per 100 contacts with a cancer. These
comprised both clinical treatments (at a rate of 16.9 per 100 contacts) and procedural
treatments (23.8 per 100 contacts).
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The GP referred the patient to another health professional or treatment service at a rate of
20.0 per 100 contacts with cancer. The majority of these referrals were to a specialist (18.5 per
100 cancer contacts). Other referrals were to an allied health service (2.6 per 100) or to a
hospital or emergency department (1.0 per 100).
Pathology tests were ordered at a rate of 26.5 tests (or groups of tests) per 100 contacts with
cancer and imaging tests were ordered at a rate of 4.5 per 100 contacts.
Table 13 summarises the types of medication prescribed for problems involving a cancer.
The most common medication type (opioids) accounted for nearly a quarter (24.8%) of these
prescriptions. The top ten types of medication together accounted for around 70% of these
prescriptions.
Table 14 summarises the types of other treatments provided by GPs for problems involving a
malignancy. Treatments involving removal of tissue comprised 40.6% of treatments
performed by GPs for cancer. The top ten treatments together accounted for 97.8% of
treatments performed by GPs for cancer.
Table 15 summarises referrals by GPs to another health professional or treatment service for
problems involving a cancer. More than half (58.9%) of these referrals were to a
dermatologist, surgeon or plastic surgeon. The top ten referral types accounted for 86.0% of
all referrals for cancers.
Table 11: Top 10 types of cancer managed at GP–patient encounters
Type of cancer Number
Estimated national number
of contacts per year
Rate per 1,000
encounters
Percentage of  total
cancer contacts
Basal cell carcinoma 1,956 511,800 4.9 25.9
Squamous cell carcinoma 1,002 262,200 2.5 13.3
Prostate cancer 916 239,700 2.3 12.1
Breast cancer (female) 650 170,100 1.6 8.6
Lung cancer 347 90,800 0.9 4.6
Melanoma 293 76,700 0.7 3.9
Other skin cancer 233 61,000 0.6 3.1
Large bowel cancer 218 57,000 0.5 2.9
Colon cancer 176 46,100 0.4 2.3
Lymphoma 133 34,800 0.3 1.8
All cancers 7,560 1,978,800 18.8 100.0
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Table 12: GPs’ management of cancer
Rate per 100 cancer contacts
Number Rate 95% confidence interval
Medications
All medications 2,345 31.0 29.3–32.8
Prescribed medications 2,191 29.0 27.3–30.7
Advised over-the-counter medications 45 0.6 0.4–0.7
Medications supplied by GP 109 1.4 1.2–1.6
Other treatments given
All treatments 3,081 40.8 38.7–42.8
Clinical treatments 1,280 16.9 15.8–18.0
Procedural treatments 1,801 23.8 22.4–25.3
Referrals
All referrals 1,515 20.0 13.6–26.5
Referrals to a hospital 78 1.0 0.0–23.5
Referrals to a specialist 1,396 18.5 11.6–25.3
Referrals to allied health services 196 2.6 0.0–11.7
Referrals to an emergency department 2 0.0 n/a
Pathology tests ordered 2,000 26.5 23.1–29.8
Imaging tests ordered 338 4.5 0.5–8.5
Table 13: Top ten medications prescribed by GPs for management of cancer
Per cent of all
prescriptions
Rate per 100 cancer
contacts
ATC(a) class of medication Number
Per
cent
95% confidence
interval Rate
95% confidence
interval
Opioids 543 24.8 21.3–28.3 7.2 3.1–11.2
Hormones and related agents 250 11.4 6.3–16.5 3.3 0.0–6.6
Other analgesics and antipyretics 200 9.1 4.1–14.1 2.7 0.0–7.0
Hormone antagonists and related agents 177 8.1 2.7–13.5 2.3 0.0–6.8
Corticosteroids for systemic use, plain 86 3.9 0.0–9.7 1.1 0.0–6.6
Propulsives 84 3.8 0.0–10.1 1.1 0.0–8.0
Hypnotics and sedatives 63 2.9 0.0–10.1 0.8 0.0–6.8
Antipsychotics 42 1.9 0.0–8.1 0.6 0.0–7.1
Antiandrogens 40 1.8 0.0–11.8 0.5 0.0–8.3
Anxiolytics 37 1.7 0.0–11.0 0.5 0.0–8.9
All classes 2,191 100.0 n/a 29.0 25.3–32.7
(a) Anatomical Therapeutic Chemical classification index, WHO Collaborating Centre for Drug Statistics Methodology.
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Table 14: Top ten treatments used by GPs for management of cancer
Per cent of all  other
treatments
Rate per 100 cancer
contacts
Treatment Number Rate
95%
confidence
interval Rate
95% confidence
interval
Excision/removal
tissue/Biopsy/Destruction/Debridement/Cauterisation 1,313 42.6 39.4–45.8 17.4 14.1–20.6
Therapeutic counselling/Listening 595 19.3 14.8–23.8 7.9 4.1–11.6
Observation/Health education/advice 550 17.9 14–21.7 7.3 4.6–10
Repair/Fixation-suture/Cast/Prosthetic device
(Apply/remove) 252 8.2 3.1–13.3 3.3 0.0–7.0
Administrative procedure 83 2.7 0–11.5 1.1 0.0–6.7
Local injection/Infiltration 71 2.3 0–12.1 0.9 0.0–8.4
Dressing/Pressure/Compression/Tamponade 58 1.9 0–12.4 0.8 0.0–7.9
Clarification/Discussion of patient’s reason(s) for
encounter(s)/demand 42 1.4 0–9.9 0.6 0.0–6.3
Other therapeutic procedures/Surgery not elsewhere
specified 28 0.9 0–22.7 0.4 0.0–12.6
Physical medicine/Rehabilitation 21 0.7 0–23.7 0.3 0.0–13.1
All treatments 3,081 100.0 n/a 40.8 38.2–43.3
Table 15: Top ten referrals made by GPs in management of cancer
Per cent of total  referrals Rate per 100 cancer contacts
Service or specialist type referred to Number Rate
95% confidence
interval Rate
95% confidence
interval
Dermatologist 366 24.0 17.6–30.4 4.8 0.5–9.1
Surgeon 334 21.9 15.8–28.0 4.4 1.5–7.3
Plastic surgeon 193 12.7 2.7–22.6 2.6 0.0–7.0
Oncologist 96 6.3 0.0–17.3 1.3 0.0–5.9
Urologist 80 5.3 0.0–19.4 1.1 0.0–7.5
Hospital 78 5.1 0.0–18.3 1.0 0.0–7.6
Specialist 64 4.2 0.0–17.9 0.9 0.0–6.2
Health professional not elsewhere
specified 33 2.2 0.0–27.0 0.4 0.0–10.1
Gastroenterologist 30 2.0 0.0–21.3 0.4 0.0–12.7
Palliative care 29 1.9 0.0–25.1 0.4 0.0–8.8
All referrals 1,515 100.0 n/a 20.0 18.3–21.8
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Summary tables 1999
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Tables for selected cancers
1999
• Tables of new cases, deaths, incidence and mortality rates for Australia and the States
and Territories for selected cancers.
• Tables for other cancer sites can be found on the AIHW’s web site at www.aihw.gov.au
or can be requested in hard copy from the AIHW.
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Appendix A: International Classification of Diseases,
10th Revision—cancer site—codes and
combinations
Buccal cavity
Lip C00
Tongue C01–C02
Salivary glands C07–C08
Gum C03
Floor of mouth C04
Other and unspecified parts of mouth C05–C06
Pharynx
Oropharynx C09–C10
Nasopharynx C11
Hypopharynx C12–C13
Other sites within the lip, oral cavity
and pharynx
C14
Head and neck C01–C14
Digestive organs and peritoneum
Oesophagus C15
Stomach C16
Small intestine C17
Colon C18
Rectum & anus C19–C21
Colorectal C18–C21
Liver and intrahepatic bile ducts C22
Gallbladder and extrahepatic bile
ducts
C23–C24
Pancreas C25
Retroperitoneum and peritoneum C48
Respiratory system
Nasal cavities, middle ear and
accessory sinuses
C30–C31
Larynx C32
Trachea, bronchus and lung C33–C34
Thymus, heart, mediastinum & pleura C37–C38
Bone, connective tissue, skin and
breast
Bone and articular cartilage C40–C41
Connective and other soft tissue C47, C49
Melanoma C43
Non-melanocytic skin cancer (NMSC) C44
Breast C50
Genitourinary organs
Vulva C51
Vagina C52
Cervix C53
Corpus uteri C54–C55
Ovary C56
Other & unspecified female genital
organs
C57
Placenta C58
Prostate C61
Testis C62
Penis and other male genital organs C60, C63
Bladder C67
Kidney, ureter and urethra C64–C66, C68
Other and unspecified organs
Eye C69
Brain C71
Other and unspecified parts of the
nervous system (NS)
C70, C72
Thyroid gland C73
Other endocrine glands C74–C75
Unknown primary site C76–C80, C26,
C39
Lymphatic and haematopoietic
tissue
Non-Hodgkin’s lymphomas (NHL) C82–C85, C96
Hodgkin’s disease C81
All lymphomas C81–C85, C96
Multiple myeloma C90
Immunoproliferative neoplasms C88
Lymphoid leukaemia C91
Acute lymphoblastic leukaemia C91.0
Chronic lymphocytic leukaemia C91.1
Myeloid leukaemia C92
Acute myeloid leukaemia C92.0
Chronic myeloid leukaemia C92.1
Monocytic leukaemia C93
Other leukaemias of specified cell type C94
Leukaemia of unspecified cell type C95
All leukaemias C91–C95
Smoking-related cancers (aetiological
fractions are applied to the following
codes)
C00–C06,
C09–C16,
C21.0, C21.2,
C21.8, C25,
C32–C34, 51.9,
C60, C67,
C64–C65
Alcohol-related cancers (aetiological
fractions are applied to the following
codes)
C01–C06,
C09–C10,
C12–C15, C22,
C32, C50
(sex= female)
Source: World Health Organization 1992.
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Appendix B: Methods
This section describes the methods used to calculate the estimates presented in the tables in
this report. The calculations in the example below are applicable to both incidence and
mortality.
Example table
Trachea, bronchus and lung cancer incidence (ICD-10 C33–34)—males
No. of cases
Australian 1999
male
population*
Age-specific
rate per
100,000
population
Australian 1991
Population
Standard**
Expected
number of
cases
Age
group (column 1) (column 2) (column 3) (column 4) (column 5)
0–4 0 660,983 0.0 1,271,703 0.0
5–9 0 689,409 0.0 1,272,208 0.0
10–14 0 681,235 0.0 1,241,619 0.0
15–19 0 671,839 0.0 1,364,074 0.0
20–24 1 660,137 0.2 1,396,764 2.1
25–29 4 732,082 0.5 1,399,663 7.6
30–34 11 704,518 1.6 1,425,735 22.3
35–39 25 751,975 3.3 1,328,387 44.2
40–44 52 707,868 7.3 1,294,271 95.1
45–49 122 664,622 18.4 1,029,145 188.9
50–54 239 614,757 38.9 846,934 329.3
55–59 402 468,982 85.7 725,950 620.7
60–64 609 384,553 158.4 736,868 1,165.0
65–69 907 334,644 271.0 671,390 1,819.7
70–74 1,100 296,140 371.4 510,755 1,897.2
75–79 985 212,337 463.9 384,495 1,783.6
80–84 492 112,785 436.2 229,828 1,002.6
85+ 326 72,058 452.4 154,247 695.7
Total 5,275 9,420,924 56.0 17,284,036 56.0
* Australian Bureau of Statistics 2000a.
** Australian Bureau of Statistics 1993.
Crude rates—all age groups
A crude incidence rate is defined as the number of new cases of cancer divided by the
population at risk in a specified time period. A crude mortality rate substitutes deaths for
new cases in this calculation. Both are conventionally expressed as annual rates per 100,000
population and may be calculated for males, females or persons, or for subsets of the
population (for example, see age-specific rates). The total rate calculated in this way without
adjustment for age or other factors is known as the ‘crude rate’.
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The crude rate is calculated by dividing the total number of cases across all age groups by
the total population, for example:
Column 1 total
x 100,000Crude incidence rate for lung cancer =
5,275
9,420,924
=
=  56.0 per 100,000
Column 2 total
x 100,000
Age-specific rates
Age-specific rates are calculated by dividing the number of cases occurring in each specified
age group by the corresponding population in the same age group expressed as a rate per
100,000 population. This rate may be calculated for particular age and sex groupings, for
example:
Column 1 for this age
x 100,000
Age-specific lung
cancer incidence
rates in males
aged 75–79
=
985
212,337
=
=  463.9 per 100,000
Column 2 for this age
x 100,000
Age-standardised rates (AS rate)
Rates are adjusted for age to facilitate comparisons between populations which have
different age structures, for example, between youthful and ageing communities. There are
two different methods commonly used to adjust for age. In this publication direct
standardisation is used, in which age-specific rates are multiplied against a constant
population (the Australian 1991 Population Standard or the new WHO World Standard
Population). This effectively removes the influence of age structure on the summary rate
which is described as the age-standardised rate. The method may be used for both incidence
and mortality calculations. The method used for this calculation comprises three steps which
can be followed by reference to the example table on the previous page.
Step 1 Calculate the age-specific rate (as shown above) for each age group (column 3).
Step 2 Calculate the expected number of cases in each 5-year age group by multiplying the
age-specific rates (column 3) by the corresponding standard population (column 4)
and dividing by 100,000, giving you the expected number of cases (column 5).
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Step 3 To give the age-standardised rate, sum the expected number of cases in each age
group (total column 5). Divide this sum by the total of the standard population used
in the calculation and multiply by 100,000.
Confidence intervals (Cl)
The age-standardised and crude incidence and mortality rates presented in the body of this
report also show 95% confidence intervals. These confidence intervals indicate the variation
that might be expected in such estimates purely by chance. The confidence intervals are
calculated using the methods presented in Holman et al. (1987).
A relatively simple approximation of the confidence limits that readers might use when
examining State and Territory age-standardised rates is as set out below.
95% CI approximation = AS rate ± 1.96 x AS rate
Number of cases
Lifetime risk and cumulative rate
Lifetime risk is a measure which approximates the risk of contracting a particular cancer in a
lifetime if the risks at the time of estimation remained throughout life. It is based on a
mathematical relationship with the cumulative rate and is calculated in this publication for
ages 0–74.
Cumulative rate is a directly standardised rate calculated by summing age-specific rates
from equal age groups, for example, 5–9, 10–14 years. An example is provided below.
5 x (Sum of the age-specific rates) x 100
100,000
Cumulative rate =
5 x 956.3 x 100
100,000
=
=  4.78%
The factor of 5 is used to indicate the 5 years of life in each age group and the factor of 100 is
used to present the result as a percentage. As age-specific rates are presented per 100,000
population (column 3), the result is divided by 100,000 to return the age-specific rates to a
division of cases by population. Cumulative risk is related to cumulative rate by the
expression:
1
−
e− rate 100( )Cumulative risk      =
where rate is expressed as a percentage.
Lifetime risk is expressed as a ‘1 in n’ proportion by taking the inverse of the above formula:
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1
1
−
e−rate  100(  )n      =
For lung cancer in men, the cumulative rate was 4.78%, therefore:
1
1
−
e − 4.78 100( )n    =
=       21.42
That is, for men, the lifetime risk (0–74 years) of developing lung cancer is 1 in 21, providing
they remain at risk for the whole period and the 1999 age-specific rates apply throughout
their lives. Note that no account has been taken of specific cancer risk factors, for example,
the risk for men who smoke would be higher than that for those who have never smoked.
Per cent of all cancers
The ‘per cent of all cancers’ measure is the proportion of all causes accounted for by a
particular cancer. The measure may be computed for cancer incidence or mortality. Using an
incidence example, the measure is calculated by taking the number of new cases of a
particular cancer, for example, lung cancer, and dividing that by the total number of all new
cancer cases and multiplying by 100 to express it as a percentage. This is undertaken for each
sex and for total persons. Note that for this publication the incidence and mortality of non-
melanocytic skin cancers is not included in total new cancer cases.
Sex ratio
This measure indicates the relative incidence or mortality between the sexes. It can be
calculated on the basis of observed numbers, crude rates, age-standardised rates or
cumulative rates per cent. In this publication it is calculated using the age-standardised rates
where the male rate is divided by the female rate for each cancer. Ratios greater than 1
indicate an excess in males while ratios less than 1 indicate an excess in females.
It is preferable to use either the age-standardised rates or the cumulative rate as these both
adjust for age variations between male and female populations. In addition, the use of
cumulative rate per cent discounts the occurrence of cancer in people aged over 75. This
gives more emphasis, therefore, to early cancer diagnosis or death, and diminishes the
impact of variable diagnostic investigation of the elderly.
Person-years of life lost
Person-years of life lost is a concept which attempts to measure the number of years of life
lost per annum due to death as a result of a specific cause, for example, lung cancer, given
life expectancies at specific ages. Age groups 0–4 up to 70–74 were used for the calculations,
as deaths before age 75 are regarded as premature for both men and women. The method
used in this publication for the calculation of person-years of life lost is an aggregation of
years between age at death and 75 for each person for each cancer, for example, a person
dying at age 50 contributes 25 years to the measure of person-years of life lost.
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Average annual rates of change
To indicate the extent of change in age-standardised rates over time, a linear line of best fit is
calculated for the time frame in question. Average annual rates of change are then calculated
using the geometric formula:
Average rate of change = ( )( )1/ /1 −Non PP  x 100
where nP = rate at later year n
oP = rate at earlier year o
N = on − .
This process averages out variations in the actual annual changes that may have occurred
between the two points in time.
104
Appendix C: Population data
Australian resident population, 1999
1999
Age Males Females Total
0–4 660,983 627,210 1,288,193
5–9 689,409 654,412 1,343,821
10–14 681,235 648,964 1,330,199
15–19 671,839 640,411 1,312,250
20–24 660,137 641,561 1,301,698
25–29 732,082 735,739 1,467,821
30–34 704,518 715,723 1,420,241
35–39 751,975 761,005 1,512,980
40–44 707,868 717,967 1,425,835
45–49 664,622 667,606 1,332,228
50–54 614,757 599,375 1,214,132
55–59 468,982 456,165 925,147
60–64 384,553 386,244 770,797
65–69 334,644 346,612 681,256
70–74 296,140 333,844 629,984
75–79 212,337 281,501 493,838
80–84 112,785 183,795 296,580
85+ 72,058 165,099 237,157
Total 9,420,924 9,563,233 18,984,157
Source: Australian Bureau of Statistics 2000a.
Australian Standard Population and World Standard Population
Australian Standard Population* (1991) New WHO World Standard Population**(2002)
Age % of total % of total
0–4 1,271,703 7.4 8,800 8.8
5–9 1,272,208 7.4 8,700 8.7
10–14 1,241,619 7.2 8,600 8.6
15–19 1,364,074 7.9 8,500 8.5
20–24 1,396,764 8.1 8,200 8.2
25–29 1,399,663 8.1 7,900 7.9
30–34 1,425,735 8.2 7,600 7.6
35–39 1,328,387 7.7 7,200 7.2
40–44 1,294,271 7.5 6,600 6.6
45–49 1,029,145 6.0 6,000 6.0
50–54 846,934 4.9 5,400 5.4
55–59 725,950 4.2 4,600 4.6
60–64 736,868 4.3 3,700 3.7
65–69 671,390 3.9 3,000 3.0
70–74 510,755 3.0 2,200 2.2
75–79 384,495 2.2 1,500 1.5
80–84 229,828 1.3 900 0.9
85+ 154,247 0.9 600 0.6
Total 17,284,036 100.0 100,000 100.0
* Australian Bureau of Statistics 1993.
**WHO at http://www3.who.int/whosis/whsa/whsa_table4_asdr_discussion.cfm
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Appendix D: Cancer registration in Australia
The table below provides information about cancer registration in Australia. Each State and
Territory operates its own registry. Generally, operational guidelines for each of the
registries are similar and coincide with the objectives of the International Association of
Cancer Registries. Although some registries operate under different coding systems for site,
morphology and other variables, the bulk of information is directly comparable and has been
reconciled for this publication. The reporting sources of the registries vary according to the
local conditions and those bodies named in the legislation. Every attempt is made to report
all cancer cases, although not every case will be identified. Cancer registries are dependent
upon their reporting sources. Variation in reporting of cancers by age, sex, type,
geographical location, country of birth or other variables does occur and may have effects on
the final statistics. Occasionally, delays in reporting some case information may extend over
several years but this has a minimal effect on the final reported data. In order to minimise
the effects on the final reported registration, multiple reporting sources are used to compile
case information where possible. Case information is exchanged between registries where
there is cause for suspicion of duplicate registration. Further information regarding registry
coding practices may be obtained by contacting the Registrar in each State or Territory.
States and Territories NSW Vic Qld WA SA Tas ACT NT
Total population (1999) 6,438,641 4,700,702 3,508,571 1,854,413 1,499,204 472,020 313,762 194,155
Per cent of Australian
population 33.9 24.8 18.5 9.8 7.9 2.5 1.7 1.0
Per cent of population
older than age 65 12.9 12.8 11.4 10.7 14.3 13.3 8.1 3.4
No. new cancers
(1995–1999)* 27,429 20,425 14,715 6,859 7,098 2,180 995 376
First year of population
registration 1972 1982 1982 1982 1977 1978 1972 1981
Year of legislation 1972 1982 1982 1981 1977 1992 1994 1991
Funding source Pvte–Govt Pvte–Govt Govt Govt Govt Pvte–Govt Govt Govt
ICD site coding ICD-O-2 ICD-O-2 ICD-O-2 ICD-O-2 ICD-O-2 ICD-O-2 ICD-O-2 ICD-O-2
Morphology coding ICD-O-2 ICD-O-2 ICD-O-2 ICD-O-2 ICD-O-2 ICD-O-2 ICD-O-2 ICD-O-2
Reporting sources
Public hospitals Yes Yes Yes No** Yes Yes Yes Yes
Private hospitals Yes Yes Yes No** Yes Yes Yes No
Repatriation hospitals Yes Yes Yes No** Yes Yes Yes No
Pathology laboratories Yes Yes Yes Yes Yes Yes Yes Yes
Radiotherapy units Yes Yes Yes Yes Yes Yes Yes No
Nursing homes Yes No Yes No No No** Yes No
Registrar of Births, Deaths
and Marriages Yes Yes Yes Yes Yes Yes Yes Yes
Doctors No** No** No** No** No** No** No** No**
* Refers to the average number of new cases over the 5-year period 1995–1999.
** Data are provided on special request only.
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Appendix E: Cancer registries contact list
New South Wales Central Cancer
Registry
New South Wales Cancer Council
LMB 1
KINGS CROSS NSW 1340
Phone: +61 2 9334 1902
Fax: +61 2 9368 0843
E-mail: ccr@nswcc.org.au
Home page: www.nswcc.org.au
Registry Manager: Ms Elizabeth Tracey
E-mail: etracey@nswcc.org.au
Phone: +61 2 9334 1974
Victorian Cancer Registry
The Cancer Council Victoria
1 Rathdowne Street
CARLTON SOUTH VIC 3053
Phone: +61 3 9635 5000
Fax: +61 3 9635 5210
Home page: www.cancervic.org.au
Director: Professor Graham Giles
Director Cancer Epidemiology Centre,
Deputy Director Cancer Control Research
Institute
1 Rathdowne Street
CARLTON SOUTH VIC 3053
E-mail: ggg@cancervic.org.au
Phone: +61 3 9635 5155
Director Information Systems:
Ms Helen Farrugia
E-mail: helenf@ cancervic.org.au
Phone: +61 3 9635 5318
Information Manager:
Mrs Vicky Thursfield
E-mail: vickyt@ cancervic.org.au
Phone: +61 3 9635 5162
Northern Territory Cancer Registry
Health Gains Planning Unit
Northern Territory Department of Health
and Community Services
PO Box 40596
CASUARINA NT 0811
Phone: +61 8 8999 2977
Fax: +61 8999 2618
Director & Registrar: Dr John Condon
E-mail: john.condon@nt.gov.au
Phone: +61 8 8999 2977
Fax: +61 8 8999 2600
Western Australian Cancer Registry
Health Information Centre
Health Department of Western Australia
PO Box 8172
Stirling Street
PERTH WA 6849
Phone: +61 8 9222 4022/4249
Fax: +61 8 9222 4236
E-mail: wacanreg@health.wa.gov.au
Home page: www.health.wa.gov.au
Director & Registrar: Dr Tim Threlfall
E-mail: tim.threlfall@health.wa.gov.au
Tasmanian Cancer Registry
Menzies Centre for Population Health
Research
GPO Box 252-23
HOBART TAS 7001
Phone: +61 3 6226 7706
Fax: +61 3 6226 7704
Home page: www.menzies.utas.edu.au/
Director: Dr Alison Venn
E-mail: Alison.Venn@utas.edu.au
Phone: +61 3 6226 7706
Registrar: Shevaun Pavlides
E-mail: shevaun.pavlides@utas.edu.au
Phone: +61 3 6226 7714
Fax: +61 3 6226 7704
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Queensland Cancer Registry
Queensland Cancer Fund
Locked Bag 1450
SPRING HILL POST OFFICE QLD 4004
Phone: +61 7 3258 2331
Fax: +61 7 3258 2345
Home page: www.qldcancer.com.au/
Director: Dr Joanne Aitken
Queensland Cancer Fund
553 Gregory Terrace, Fortitude Valley
Locked Bag 1450
SPRING HILL POST OFFICE QLD 4004
E-mail: joannea@qcfepi.org.au
Phone: +61 7 3258 2309
Fax: +61 7 3258 2345
Registrar: Ms Di Skilton
E-mail: diana_skilton@health.qld.gov.au
Phone: +61 7 3258 2333
Fax: +61 7 3258 2345
South Australian Cancer Registry
Epidemiology Branch, Dept of Human
Services
PO Box 6
RUNDLE MALL SA 5000
Phone: +61 8 8226 6372
Fax: +61 8 8226 6291
Home page: www.dhs.sa.gov.au/pehs/
disease-control-status.htm
Director: Dr Colin Luke
E-mail: Colin.Luke@dhs.sa.gov.au
Phone: +61 8 8226 6360
Specialist Medical Officer (Public Health
Physician), Medical Director/Manager:
Dr Wayne Clapton
E-mail: Wayne.Clapton@dhs.sa.gov.au
Phone: +61 8 8226 6362
Registrar: Lesley Milliken
E-mail: Lesley.Milliken@dhs.sa.gov.au
Phone: +61 8 8226 6372
Australian Capital Territory Cancer
Registry
Australian Capital Territory Cancer Registry
Population Health Research Centre
ACT Health
Level 1, Building 5, The Canberra Hospital
PO Box 11
WODEN ACT 2606
Manager: Sally Rubenach
E-mail: sally.rubenach@act.gov.au
Phone: +61 2 6244 2174
Fax: +61 2 6244 4138
Registrar: Dr Berrin Kose
E-mail: berrin.kose@act.gov.au
Phone: +61 2 6244 4285
New Zealand Cancer Registry
Clinical Coding Services
New Zealand Health Information Service
Level 6, WestpacTrust House
119–125 Willis Street
PO Box 5013
Wellington New Zealand
Phone: +64 4 922 1800
Fax: +64 4 922 1897
Team Leader: Christine Fowler
E-mail: christine.fowler@nzhis.govt.nz
Phone: +64 4 922 1864
Chief Analyst: Jim Fraser
E-mail: jim.fraser@nzhis.govt.nz
Phone: +64 4 922 1862
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Appendix F: Tables published on the Internet
Table 1: All cancers (ICD-10 C00–97 except non-melanocytic skin cancers C44)
Table 2: Cancer of the lip (ICD-10 C00)
Table 3: Cancer of the tongue (ICD-10 C01–C02)
Table 4: Cancer of the salivary gland (ICD-10 C07–C08)
Table 5: Cancer of the mouth (ICD-10 C03–C06)
Table 6: Cancer of the gum (ICD-10 C03)
Table 7: Cancer of the floor of mouth (ICD-10 C04)
Table 8: Cancer of palate and other and unspecified parts of mouth (ICD-10 C05–C06)
Table 9: Cancer of the tonsil (ICD-10 C09)
Table 10: Cancer of the oropharynx (ICD-10 C10)
Table 11: Cancer of the tonsil and oropharynx (ICD10 C09–C10)
Table 12: Cancer of the nasopharynx (ICD-10 C11)
Table 13: Cancer of the hypopharynx (ICD-10 C12–C13)
Table 14: Cancer of other and ill-defined sites within the lip, oral cavity and pharynx
(ICD-10 C14)
Table 15: Cancer of the head and neck (ICD-10 C01–C14)
Table 16: Cancer of the oesophagus (ICD-10 C15)
Table 17: Cancer of the stomach (ICD-10 C16)
Table 18: Cancer of the small intestine (ICD-10 C17)
Table 19: Cancer of the colon (ICD-10 C18)
Table 20: Cancer of the rectum (ICD-10 C19–C20)
Table 21: Cancer of the anus (ICD-10 C21)
Table 22: Cancer of the colon and rectum (including anus) (ICD-10 C18–C21)
Table 23: Cancer of the colon and rectum (excluding anus) (ICD-10 C18–C20)
Table 24: Cancer of the liver and intrahepatic bile ducts (ICD-10 C22)
Table 25: Cancer of the gallbladder and extrahepatic bile ducts (ICD-10 C23–C24)
Table 26: Cancer of the pancreas (ICD-10 C25)
Table 27: Cancer of the nasal cavities, middle ear and accessory sinuses (ICD-10 C30–C31)
Table 28: Cancer of the larynx (ICD-10 C32)
Table 29: Cancer of the trachea, bronchus and lung (ICD-10 C33–C34)
Table 30: Cancer of the thymus, heart, mediastinum and pleura (ICD-10 C37–C38)
Table 31: Cancer of the bone and articular cartilage (ICD-10 C40–C41)
Table 32: Cancer of the skin—melanoma (ICD-10 C43)
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Table 33: Cancer of the skin—non-melanocytic (ICD-10 C44)
Table 34: Mesothelioma (ICD-10 C45)
Table 35: Kaposi’s sarcoma (ICD-10 C46)
Table 36: Cancer of the peripheral nerves and autonomic nervous system (ICD-10 C47)
Table 37: Cancer of the retroperitoneum and peritoneum (ICD-10 C48)
Table 38: Cancer of other connective and soft tissue (ICD-10 C49)
Table 39: Cancer of other connective and soft tissue and autonomic nervous system
(ICD-10 C47–C49)
Table 40: Cancer of the breast (ICD-10 C50)
Table 41: Cancer of the vulva (ICD-10 C51)
Table 42: Cancer of the vagina (ICD-10 C52)
Table 43: Cancer of the cervix uteri (ICD-10 C53)
Table 44: Cancer of the corpus uteri (ICD-10 C54)
Table 45: Cancer of the uterus unspecified (ICD-10 C55)
Table 46: Cancer of the corpus uteri and uterus unspecified (ICD-10 C54–C55)
Table 47: Cancer of the ovary (ICD-10 C56)
Table 48: Cancer of the other and unspecified female genital organs (ICD-10 C57)
Table 49: Cancer of the placenta (ICD-10 C58)
Table 50: Cancer of the penis (ICD-10 C60)
Table 51: Cancer of the prostate (ICD-10 C61)
Table 52: Cancer of the testis (ICD-10 C62)
Table 53: Cancer of the other and unspecified male genital organs (ICD-10 C63)
Table 54: Cancer of the penis and other and unspecified male genital organs
(ICD10 C60, C63)
Table 55: Cancer of the kidney (ICD-10 C64)
Table 56: Cancer of the renal pelvis (ICD-10 C65)
Table 57: Cancer of the ureter (ICD-10 C66)
Table 58: Cancer of the bladder (ICD-10 C67)
Table 59: Cancer of the other urinary organs (ICD-10 C68)
Table 60: Cancer of the kidney and other urinary organs (ICD-10 C64–C66, C68)
Table 61: Cancer of the eye (ICD-10 C69)
Table 62: Cancer of the brain (ICD-10 C71)
Table 63: Cancer of the meninges and other central nervous system (ICD-10 C70, C72)
Table 64: Cancer of the brain and nervous system (ICD-10 C70–C72)
Table 65: Cancer of the thyroid gland (ICD-10 C73)
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Table 66: Cancers of the adrenal glands (ICD-10 C74)
Table 67: Cancers of other endocrine glands (ICD-10 C75)
Table 68: Cancer of the adrenal glands and other endocrine glands (ICD10 C74, C75)
Table 69: Cancers of unknown primary site (ICD-10 C76–C80, C26, C39)
Table 70: Hodgkin’s disease (ICD-10 C81)
Table 71: Non-Hodgkin’s lymphoma (ICD-10 C82–C85, C96)
Table 72: Lymphoma NOS (ICD-O-2 M9590/3)
Table 73: All lymphomas (ICD-10 C81–C85, C96)
Table 74: Immunoproliferative neoplasms (ICD-10 C88)
Table 75: Multiple myeloma (ICD-10 C90)
Table 76: Lymphoid leukaemia (ICD-10 C91)
Table 77: Acute lymphoblastic leukaemia (ICD-10 C91.0)
Table 78: Chronic lymphocytic leukaemia (ICD-10 C91.1)
Table 79: Myeloid leukaemia (ICD-10 C92)
Table 80: Acute myeloid leukaemia (ICD-10 C92.0)
Table 81: Chronic myeloid leukaemia (ICD-10 C92.1)
Table 82: Monocytic leukaemia (ICD-10 C93)
Table 83: Other leukaemias of specified cell type (ICD-10 C94)
Table 84: Leukaemia of unspecified cell type (ICD-10 C95)
Table 85: Other and unspecified malignant neoplasms of lymphoid, haematopoietic and
related tissues (ICD-10 C96)
Table 86: All leukaemias (ICD-10 C91–95)
Table 87: Malignant neoplasms of independent (primary) multiple sites (ICD-10 C97)
Table 88: Alcohol-related cancers
Table 89: Smoking-related cancers
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Glossary
AACR: Australasian Association of Cancer Registries
ABS: Australian Bureau of Statistics
ACT: Australian Capital Territory—a land-locked Territory of Australia situated within the
State of New South Wales on the eastern seaboard, with a population of 313,762 (1999). Its
capital city is Canberra, which is also Australia’s capital city.
Additional diagnosis: conditions or complaints either co-existing with the principal
diagnosis or arising during the episode of care. Additional diagnoses give information on
factors that result in increased length of stay, more intensive treatment or the use of greater
resources.
Admitted patient: a patient who undergoes a hospital’s formal admission process to receive
treatment and/or care. This treatment and/or care is provided over a period of time and can
occur in hospital and/or in the person’s home.
AIHW: Australian Institute of Health and Welfare
AMWAC: Australian Medical Workforce Advisory Committee
AS rate (ASR): age-standardised rate. See Appendix B for definition.
Australian Refined Diagnosis Related Groups (AR-DRGs): an Australian system of
Diagnosis Related Groups (DRGs). DRGs provide a clinically meaningful way of relating the
number and type of patients treated in a hospital to the resources required by the hospital.
Each AR-DRG represents a class of patients with similar clinical conditions requiring similar
hospital services.
Average length of stay (ALOS): the average length of stay is the ratio of the number of
patient days to the number of separations. This is calculated excluding same-day patients.
Cancer (malignant neoplasm): a term used to describe one of several diseases which result
when the process of cell division, by which tissues normally grow and renew themselves,
becomes uncontrolled and leads to the development of malignant cells. These cancer cells
multiply in an uncoordinated way, independently of normal growth control mechanisms, to
form a tumour. This tumour may expand locally by invasion or systemically by metastasis
via the lymphatic or vascular systems. If left untreated most malignant tumours will
eventually result in death. (See ‘What is cancer?’ on page 1.)
Cancer death: a death for which the underlying cause is indicated as cancer. Persons with
cancer who die of other causes are not counted in the death statistics in this publication.
Care type: the care type defines the overall nature of a clinical service provided to an
admitted patient during an episode of care
CI: confidence interval
CNS: central nervous system
Epidemiology: the quantitative study of the distribution and determinants of health-related
states and events in populations, and the application of this study to the control of health
problems
Establishment sector: a section of the health care industry,that is, public hospitals, private
hospitals
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Funding source: expected principal source of funds for an admitted patient episode or non-
admitted patient service event
GP: general practitioner
GPSCU: General Practice Statistics and Classification Unit
ICD-10: International Classification of Diseases—a coding system used to identify the
primary site of the malignancy. This publication uses the tenth revision of the ICD
classification.
Incidence: see new cancer case
Medicare eligibility status: the patient’s eligibility for Medicare as specified under the
Commonwealth Health Insurance Act 1973
ML: myeloid leukaemia
Mortality: see cancer death
NCSCH: National Cancer Statistics Clearing House
New cancer case: a person who has a new cancer diagnosed for the first time. One person
may have more than one cancer and therefore may be counted twice in incidence statistics if
it is decided that the two cancers are not of the same origin. This decision is based on a series
of principles set out in more detail in a publication by Jensen et al. (1991).
NHL: non-Hodgkin’s lymphoma
NMSC: non-melanocytic skin cancer
NOS: not otherwise specified
NS: nervous system
NSW: New South Wales—a State of Australia on the eastern seaboard which has the largest
capital city in Australia, Sydney, and a population of 6,438,641 (1999)
NT: Northern Territory—a Territory in the north of Australia, with a population of 194,155
(1999) and Darwin as its capital city
Principal diagnosis: the principal diagnosis is defined as the diagnosis established, after
study, to be chiefly responsible for occasioning the admitted patient’s episode of care in
hospital
Procedure block: the block number is a means of numerically ordering groups of related
procedure codes
PSA: prostate-specific antigen
PYLL: person-years of life lost
Qld: Queensland—a State in the north-east of Australia, with a population of 3,508,571
(1999) and Brisbane as its capital city
SA: South Australia—a State in the southern part of Australia, with a population of 1,499,204
(1999) and Adelaide as its capital city
Separation mode: status at separation of person (discharge/transfer/death) and place to
which person is released (where applicable)
SNOMED: Systematised Nomenclature of Medicine.
Tas: Tasmania—an island State in the south-east of Australia, with a population of 472,020
(1999) and Hobart as its capital city
Vic: Victoria—a State in the south-east of Australia, with a population of 4,700,702 (1999) and
Melbourne as its capital city
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WA: Western Australia—the western-most State of Australia, with a population of 1,854,413
(1999) and Perth as its capital city
WHO: World Health Organization
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Data sources
National Cancer Statistics Clearing House database
Cancer is a notifiable disease in all States and Territories. The data are collected by cancer
registries and include clinical and demographic information about people with newly
diagnosed cancer. This information is obtained from hospitals, pathologists, radiation
oncologists, cancer treatment centres and nursing homes.
The AIHW is responsible for the national collection of cancer incidence statistics through the
National Cancer Statistics Clearing House. National statistics are available for all years from
1982 to 1999.
National mortality database
Registration of deaths in Australia is the responsibility of the State and Territory Registrars
of Births, Deaths and Marriages. Information on the cause of death is supplied by the
medical practitioner certifying the death or by a coroner. Other information about the
deceased is supplied by a relative or other person acquainted with the deceased or by an
official institution where the death occurred. Registration of death is a legal requirement in
Australia, and compliance is virtually complete.
The Registrars provide deaths data to the ABS for coding and compilation into national
statistics. The AIHW also holds these data without unique identifiers in a national mortality
database.
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